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Background: There is growing availability of novel psychoactive substances (NPS),
including cognitive enhancers (CEs) which can be used in the treatment of certain mental
health disorders. While treating cognitive deficit symptoms in neuropsychiatric or
neurodegenerative disorders using CEs might have significant benefits for patients, the
increasing recreational use of these substances by healthy individuals raises many clinical,
medico-legal, and ethical issues. Moreover, it has become very challenging for clinicians to
keep up-to-date with CEs currently available as comprehensive official lists do not exist.
Methods: Using a web crawler (NPSfinder®), the present study aimed at assessing
psychonaut fora/platforms to better understand the online situation regarding CEs. We
compared NPSfinder® entries with those from the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA) and from the United Nations Office on Drugs and Crime
(UNODC) NPS databases up to spring 2019. Any substance that was identified by
NPSfinder® was considered a CE if it was either described as having nootropic abilities by
psychonauts or if it was listed among the known CEs by Froestl and colleagues.
Results: A total of 142 unique CEs were identified by NPSfinder®. They were divided into
10 categories, including plants/herbs/products (29%), prescribed drugs (17%), image
and performance enhancing drugs (IPEDs) (15%), psychostimulants (15%), miscellaneous
(8%), Phenethylamines (6%), GABAergic drugs (5%), cannabimimetic (4%), tryptamines
derivatives (0.5%), and piperazine derivatives (0.5%). A total of 105 chemically different
substances were uniquely identified by NPSfinder®. Only one CE was uniquely identified
by the EMCDDA; no CE was uniquely identified by the UNODC.
Conclusions: These results show that NPSfinder® is helpful as part of an Early Warning
System, which could update clinicians with the growing numbers and types of nootropics
in the increasingly difficult-to-follow internet world. Improving clinicians’ knowledge of NPS
could promote more effective prevention and harm reduction measures in clinical settings.
Keywords: cognitive enhancers, nootropics, novel psychoactive substances, novel psychoactive substances,
screening, early warning systemsg September 2020 | Volume 11 | Article 5467961
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Cognitive enhancement may be defined as “the amplification or
extension of core capacities of the mind through improvement or
augmentation of internal or external information processing
systems” (1). Both non-pharmacological and pharmacological
enhancers are sought by the general public in order to improve
performance during studying and at work by increasing
concentration, motivation and accuracy, via physical, behavioral
and biochemical activities (2).
Cognitive enhancer drugs (CEs) are also known as
“nootropics” (from the Greek ‘nous’ meaning ‘mind’ and
‘trepein’ meaning ‘turning/bending’), a term initially penned by
Corneliu Giurgea when piracetam was found to exhibit memory-
enhancing properties in clinical trials (3, 4). Cognitive enhancer
drugs such as modafinil improve cognition in very specific ways
such that it enhances “pattern recognition memory, digit span
recall, and mental digit manipulation” (5).
Cognitive Enhancers, Historical
Perspective and State of the Art
Historically, CEs have been used to treat conditions related to
cognition deficits such as Alzheimer’s disease, psychiatric
disorders such as schizophrenia (6), stroke or attention deficit
hyperactivity disorder (ADHD) (7–9). These phenomena
commonly occur with aging (7–9). It was found that some CEs
also improve cognitive functions in healthy subjects, such as
memory, executive functions, creativity, and motivation (10).
Their use has become more and more prevalent among college,
high school, and university students as well as in the military
(11–13).
The world of CEs is multifaceted and complex, with different
molecules acting with different modes of actions and on different
(and often multiple) receptors in the central nervous system
(CNS). “Natural” enhancers such as nicotine (14–17) and
caffeine (18) are generally accepted as substances that help us
by improving focus, alertness, and productivity. Food-based
antioxidants, herbal, and other food-derived nootropic agents
have become increasingly popular in recent times after there
have been suggestions of associations between cognition and diet
(19). Prescription drugs, such as modafinil, amphetamine, and
methylphenidate are used off-label by healthy people who do not
have specific deficits but want to improve their standards of
intellectual and cognitive performance (20). Cognitive enhancers
also include many drugs which have never reached the market as
they have been discontinued in Phase II or III clinical trials (7–9).
The many dimensions of cognitive enhancement are described
and disentangled in a recent review (2). Dresler and colleagues
(2) pointed out how cognitive enhancement is not a monolithic
phenomenon and how there are a great variety of interventionsAbbreviations: ADHD, attention deficit hyperactivity disorder; CEs, cognitive
enhancers; EDND, European Database on New Drugs; EMCDDA, European
Monitoring Centre for Drugs and Drug Addiction; EWA, Early Warning
Advisory; GABA, gamma-aminobutyric acid; IPEDs, imaging and performance
enhancing drugs; MPH, methylphenidate; NPS, novel psychoactive substances;
SSRIs, Selective Serotonin Re-uptake Inhibitors; UNODC, United Nations Office
on Drugs and Crime.
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and behavioural enhancement strategies.
Misuse of Cognitive Enhancers
The most prevalent CEs that are currently abused/misused include
diverted prescription medicines such as those used for the
treatment of attention deficit hyperactivity disorder (ADHD) i.e.
methylphenidate (MPH) and amphetamine/dextroamphetamine
(Adderall—most common brand); “wakefulness-promoting
agents” with psychostimulant effects such as modafinil (21–23);
illicit psychostimulants such as amphetamine, and drugs that act
on the glutamatergic AMPA receptors, the so-called ampakines or
“glutamate activators” (24). While the benefits of medications,
such as MPH or modafinil, in patients suffering from specific
diagnosed conditions (such as ADHD or narcolepsy) have been
studied and evaluated, the potential benefits of these substances in
heathy individuals remain unclear. The use of CEs in healthy
individuals poses significant concerns due to the lack of clinical
evidence regarding their safety, effectiveness, and social
consequences, especially with long-term use.
Urban and Gao (24) emphasized that these newly misused
drugs, i.e. MPH, may in fact improve cognition by acting on the
memory and learning circuits, thus exciting the dopamine/
glutamate/noradrenergic neurons. The modulation of these
neurotransmitters in healthy individuals seeks to enhance their
cognitive functions beyond baseline levels, but may also lead to
paradoxical effects, particularly in children’s and adolescent’s
growing brains (25). In these cases, glutamate modulation may
impair behavior flexibility, whichmay facilitate addictive behaviors.
Conversely, dopamine and norepinephrine reuptake inhibition
may lead to a hyperdopamin-/hypernoradrenalin-ergic state,
which may induce a cognition decline because the relationship
between the prefrontal cortex cognition enhancement and the
levels of both dopamine and noradrenaline is non-linear and
actually an inverted U-curve (25–27). Urban et al. (28) have also
emphasized that the use of CEs such as MPH and modafinil can
have short- and long-term impacts on plasticity in the pre-frontal
cortex that may affect the potential for plastic learning especially in
children and adolescents.
Like many other NPS, nootropics have become increasingly
easily available on the internet over the last 20 years. According
to the United Nations Office on Drugs and Crime (UNODC)
Early Warning Advisory (EWA) on new psychoactive substances
(NPS), NPS have been reported from over 100 countries and
territories from all regions of the world (29–32). In addition, the
European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) has been monitoring more than 700 NPS that have
appeared on Europe’s drug market in the last 20 years, of which
almost 90% have appeared in the last decade (33, 34). The
European Database on New Drugs (EDND) of the EMCDDA
records the notifications of new substances and the detection of
NPS in Europe (35). Although many of these identified NPS
might be used by healthy people as CEs, there are limited data on
how many or which substance is, nor are CEs classified as a
specific category. Despite being a challenging task in view of the
pharmacological differences of CEs, producing a formal
classification of these substances is crucial in order to furtherSeptember 2020 | Volume 11 | Article 546796
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monitor their use and effects.
Previous Findings and Current Challenges
Scientific data regarding NPS used or misused as CEs are lacking.
Recent research papers mostly focus on the misuse of specific
and well-known CEs such as methylphenidate analogs (36, 37),
designer benzodiazepines, phenmetrazine, modafinil, novel
synthetic opioids (37), and MPH (38). More literature is
available on CEs which are potentially able to address cognitive
deficits in specific patient groups. Froestl and Maitre (39) have
classified these molecules into 19 categories based on their
pharmacodynamics. Some of these molecules could not be
classified based on their pharmacodynamics and hence were
classified based on their chemical structure or their origin i.e. as
natural products or endogenous molecules (39). Many of these
drugs were clinically tested for their potential to improve
cognitive function. Although they all might have a potential
for being misused by the general public looking to enhance their
cognitive abilities, the vast majority of these molecules have
never reached the market as most of them have been
discontinued in Phase II or III clinical trials (7–9).
A comprehensive literature review completed by Froestl et al.
(7–9) proposed a description and a classification of 1,705molecules
as “nootropic agents or CEs” in the Thomson Reuters Pharma
database,whichwere studied for their potential to counter cognitive
deficits inAlzheimer’s disease.The largenumberofCEs, reported in
the latter review, is attributed to the fact that it contains a high
proportion (42%) ofmolecules that were tested for the treatment of
dementia andmolecules which were discontinued. Many CEs were
described as groups or families (i.e. beta-amyloid aggregation
inhibitors). These CEs were not identified by either the EDND,
EWA, or NPSfinder® as this is not part of the remit of any of the
NPS early identification systems. In particular, many categories of
CEs described by Froestl et al. (7–9) such as “Drugs interactingwith
Cytokines”, “Drugs interacting with Gene Expression”, “Drugs
interacting with Heat Shock Proteins”, “Drugs interacting with
Hormones”, “Drugs interacting with Ion Channels (different from
receptors)”, “Drugs interacting with Nerve Growth Factors”,
“Drugs interacting with Transcription Factors”, “Metal
Chelators”, “Drugs preventing amyloid-beta aggregation”, “Drugs
preventing amyloid-beta aggregation”, “Drugs interacting with
tau”, “Stem Cells” include molecules specifically targeted for
Alzheimer’s disease and, therefore, less likely to be relevant for
the NPS early identification systems.
Apart from the known families ofCEs (historically derivatives of
MPH, modafinil, and racetams), psychonauts (subjects who
experience intentionally drug-induced altered states of
consciousness (40) have been experimenting with a variety of
commonly prescribed drugs as well as illicit substances, often
finding subjective evidence of cognitive enhancement and sharing
their knowledge within the dark web sites and surface internet fora.
At present, a comprehensive, up-to-date list of currently available
CEs does not exist. Moreover, CEs are not described as a specific
category/family within the EDND or EWA databases; this is
because many substances, with many different (complex and,
sometimes, not fully understood) pharmacological mechanisms,Frontiers in Psychiatry | www.frontiersin.org 3have the potential of improving aspects of cognition. Finally, some
of these substances are not illegal (i.e. prescribed medication, food
supplements, natural remedies etc.). For these reasons, it is difficult
to create an early identification system which is able to keep
professionals up-to-date with the CEs which are currently
available to the general public via the online market.
Aims of the Study
In this study, the aims were to (a) identify and categorize the
number of CEs collected by the NPSfinder® web crawler from a
range of psychonaut, NPS-related, online sources; (b) compare
the NPSfinder® cognitive enhancers’ list with related findings
from the UNODC’s EWA and the EMCDDA’s EDND.MATERIALS AND METHODS
NPSfinder®, a Tool for the Early
Recognition of NPS
NPSfinder® is a crawling/navigating software which was
designed to facilitate the early recognition of the continuously
growing amount of NPS that are available on the internet. At
present, NPSfinder® is a password protected proprietary
software, which allows registered researchers only to screen
and classify the substances that are identified by the software.
An open access part, which will allow the general public to have
free access to the substances, is under development.
NPSfinder® automatically scans the web for new/novel/
emerging NPS, including CEs, via the identification of
psychonauts’ websites/fora. Every time a new website is
identified, all its items are scanned and compared with the
online existing ones. When a novel substance is found, this is
added to the growing NPSfinder® database. NPSfinder®
screening process is tailored to each website, and no specific
keywords are used by the software. This proprietary method,
which was created by trained software engineers, allows to map,
on a 24/7 basis, the large variety of psychoactive molecules
mentioned/discussed within a range of representative online
psychonauts’ web sites/fora. This list is continuously growing
(the current, full list of these sites is available upon request).
NPSfinder® was designed to extract a range of information
regarding NPS, including: chemical and street names; chemical
formulae; three-dimensional images and anecdotally reported
clinical/psychoactive effects.
Identification of Cognitive Enhancers
by NPSfinder®
NPSfinder® has been already successfully used to identify other
types of NPS, including synthetic cathinones (41), novel
psychedelics (42), and novel opioids (43). In each paper, the
comparison with international or European NPS databases has
shown that NPSfinder® is able to identify substances which were
not previously described by the existent early detection systems.
Raising awareness of novel substances has important implications
from both a legislative and a clinical perspective.
Between 26 November 2017 and 31 May 2019, NPSfinder®
carried out a range of open web crawling identification activitiesSeptember 2020 | Volume 11 | Article 546796
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multilingual sources with a specific focus on new/traditional
psychoactive substances of likely recreational interest. Although
the language most typically used in these websites was English,
further languages analyzedbyNPSfinder® included:Dutch, French,
German, Italian, Russian, Spanish, Swedish, and Turkish. With the
help of an ad hoc check control panel, all data were manually
examined by four medically/psychiatrically-trained professionals
(i.e. FN,DA, CZ, and LG). In this way, a full assessment and editing
of each NPSfinder® data item were conducted, and the range of
unique CEs presented here was identified.
The collection of further information was completed by
consulting a range of open libraries and chemistry databases
referring to the index item, if existing. These data were then
stored in an online, restricted access/password-controlled
database located within firewall protected, highly secure, and
consistently performing servers.
When any new item was detected during the automated web
scan, the system sent an e-mail notification/alert to the core
researchers’ mailing list. Data were then screened for relevance
and possible duplications.
The identified psychoactive substances were classified as CEs
when a cognitive enhancing ability of any kind (such as
improved attention, concentration, alertness, and memory) was
mentioned in the description and/or among the effects of the
psychoactive substance. The used terms for the search were
“nootropic”, “cognitive enhancers”, “cognition enhancement”,
“smart drugs”, “memory enhancers”, “concentration enhancers”,
“attention enhancers”, “neuro enhancers”, and “intelligence
enhancers”. Therefore, it is to be noted that these identified
CEs are thought by psychonauts as having cognitive enhancing
properties according to their subjective and anecdotical
experience rather than due to any pharmacological analysis.
When a substance that was identified by NPSfinder® was not
explicitly described as able to enhance cognitive abilities but was
listed as a known CE within the comprehensive review by Froestl
et al. (7–9), it was still included among the list of
NPSfinder® CEs.
Identification and Classification of
Cognitive Enhancers
The NPSfinder® CE results (updated to May 2019) were
compared with those reported by the UNODC’s EWA on NPS
(updated by April 2019) and the EMCDDA’s EDND (updated by
April 2019).
Using chemical structure identification and other published
information (i.e. published research papers and official databases),
researchers assigned each molecule to its drug class, using the
classification described by Schifano et al. (44, 45) for NPS. This
classification includes the following families: synthetic
cannabimimetics, synthetic cathinones, novel psychostimulants,
novel derivatives of classic psychedelics phenethylamines/
MDMA-like drugs, synthetic opioids, synthetic cocaine
substitutes, novel tryptamines derivatives, GABAergic drugs,
phencyclidine-like dissociative drugs, piperazine derivatives,
herbs/plants, prescribed drugs, and image and performance
enhancing drugs (IPEDs).Frontiers in Psychiatry | www.frontiersin.org 4RESULTS
Identification and Classification of CEs
After about 18 months of operation, the number of substances
identified by the web crawler activities was 5,922. By the time of
writing (January 2020), 4,204 unique NPS substances were
included in the database, and 1,718 out of 5,922 (29.0%)
remaining substances were found to be false positives or
duplicates. The most common NPS mentioned in psychonauts’
fora included: psychedelic phenethylamines (30.1%); synthetic
cannabimimetics (29.8%); and opioids (10.1%).
A total of 142 unique CEs was identified by NPSfinder®
(Table A1). Of these, 35 were explicitly described as having
nootropic properties by psychonauts; the remaining 107
molecules were classified as CEs as also present in the
comprehensive review on CEs written by Froestl et al. (7–9).
Using the classification described by Schifano and colleagues
(44, 45), the CEs identified by NPSfinder® (n = 142) were divided
into 10 categories; the majority of these substances were classified
as plants/herbs/products (29%), prescribed drugs (17%), image
and performance enhancing drugs (IPEDs) (15%), and
psychostimulants (15%); in addition, there were substances
classified as miscellaneous (8%), phenethylamines (6%),
GABAergic drugs (5%), cannabimimetic (4%), tryptamines
derivatives (0.5%), and piperazine derivatives (0.5%) (Table 1).
Comparison of NPSfinder® Findings With
EU and UN NPS-Related Databases
Current NPSfinder® results were compared with the EMCDDA
and the UNODC databases in order to ascertain which molecules
were also detected and listed by the official European and United
Nation early identification systems.
Out of the 142 molecules identified as CEs by NPSfinder®, a
total of 105 chemically different substances were uniquely
identified by NPSfinder®; of the remaining 37 molecules, 22
were also listed in both the EDND and EWA databases, 15 of
which were reported in both the NPSfinder® and in either the
EMCDDA (n = 11) or the UN databases (n = 4) (Table A1).
Only one CE was uniquely identified by the EDND (MIQ-001,
also called meta-IQ); no CE was uniquely identified by the
EWA database.TABLE 1 | CEs identified by NPSfinder® using Schifano et al.’s (44) classification
(n=142).
Class (44) N. of CEs
Plants/herbs/products 41 (29%)
Prescribed drugs 24 (17%)
Image and performance enhancing drugs (IPEDs) 21 (15%)
Psychostimulant drugs 21 (15%)
Miscellaneous 11 (8%)
Phenethylamines 9 (6%)
GABAergic drugs 7 (5%)
Cannabimimetic 6 (4%)
Tryptamines derivatives 1 (0.5%)
Piperazine derivatives 1 (0.5%)
TOTAL 142September 2020 | Volume 11 | Article 546796
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Identification Source
Figure 1 shows the number of CEs identified by each source
(including NPSfinder®, EDND and EWA database) as well as the
ones identified by more than one source. A full list of the CEs is
available upon request.DISCUSSION
In this paper, we aimed to evaluate whether the innovative
crawling software NPSfinder® can be employed as a helpful
tool in the early identification and prediction of CEs. In order to
achieve this goal, findings from NPSfinder® were cross-checked
with two official sources (EMCDDA’s EDND and UNODC’s
EWA). To the best of our knowledge, this is an unprecedented
list of drugs which are described as CEs and, therefore, with a
potential for recreational misuse by healthy individuals.
NPSfinder® identified 35 molecules (out of the total of 4,204)
that were described by psychonauts as having cognitive
enhancing effects, such as improved memory, alertness,
attention, and concentration. A further 107 molecules were
previously described as CE (7–9), although psychonauts did
not explicitly describe them as CE. Since psychonauts
experiment with novel substances in order to intentionally
experience altered states of consciousness, it is to be expected
that their interest also extends to the world of CEs. Among the
CEs that they have been discussing online, there are mostly
molecules that are known to have nootropic properties, are
not illegal, and are likely to be easily available on the market
(such as racetam compounds, modafinil and its derivatives,
methylphenidate and its derivatives and food supplements).Frontiers in Psychiatry | www.frontiersin.org 5Our results showed that NPSfinder® could be employed as
an Early Warning System tool to help clinicians with keeping
their knowledge up-to-date with the growing numbers and
types of nootropics in the increasingly difficult-to-follow
online market.
It is not surprising that the included sources (i.e. NPSfinder®,
EDND, and EWA) have identified mis-matching numbers and
types of CEs, as they differ in their methodology and purposes of
CE identification. In fact, the EDND was created in order to
allow the European Union to rapidly detect, assess, and respond
to health and social threats caused by NPS (35). The UNODC
EWA on NPS provides access to basic information on new
psychoactive substances, including trend data, chemical details
on individual substances, supporting documentation on
laboratory analysis and legislative responses (30). Specifically,
the EDND and EWA focus on illegal drugs and do not look at
websites that contain patented medications, while NPSfinder®
looks at websites whose contributors might have accessed
sources containing patent medications.
NPSfinder® Findings
The large number of molecules that are both identified by
NPSfinder® and described by Froestl et al. (7–9) leads us to
believe that nowadays psychonauts are discussing (and likely
using) substances that have been considered or used for the
treatment of the Alzheimer’s disease over seven years ago,
and they are doing so in order to improve their cognitive
performances in the absence of clinical reasons.
Among the CEs that have been subjectively identified by
psychonauts as able to improve certain aspects of their cognition,
there are molecules whose objective cognitive enhancing
properties have not been established by research studies, such
as the selective serotonin re-uptake inhibitors (SSRIs), melatonin
and many others.
Comparison of NPSfinder® Findings With
EDND or EWA Databases
The large number of unique molecules that were uniquely
identified by NPSfinder® can be explained with the
innovative methodology that NPSfinder® used for the early
identification of all NPS, including CEs (41–43). Being a
dynamic software, NPSfinder® is able to automatically scan
the web for new/novel/emerging NPS on a 24/7 basis. This is
indeed an effective mechanism for the early identification of
(potential) NPS, which are being discussed on the psychonauts’
websites and fora.
Description and Classification of CEs
Identified by NPSfinder®
The CEs identified by NPSfinder® (n = 142) were divided into 10
categories as shown in Table 1.
Plants/herbs/product:
The NPSfinder® family of “Plants/herbs/product” contains a list
of plant-based substances with a variety of psychoactive
ingredients (Table 2).FIGURE 1 | Number of CEs identified by EMCDDA, UNODC, and
NPSfinder® according to their identification source (n = 1,785).September 2020 | Volume 11 | Article 546796
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as: caffeine, nicotine, cinnamon, ginger root extracts, curcumin,
ginseng, coumarins, menthol, St John’s wort, Yerba mate, Bacopa
monnieri, Areca nut (and its main active ingredient arecoline),
Lemon balm, Mucuna pruriens, Peganum harmala, harmaline,
harmalol, and lobeline, some of which are commonly used by
ayurvedic traditional medicine or in other branches of alternative
medicine to improve memory and/or to treat various diseases.
Flavonoids such as quercetin and naringin, as well as vitamins A,
B, and D are also part of this group.
There are studies on the cognitive enhancing properties of
caffeine (18), nicotine (14–17), curcumin (46–48), St John’s wort
(Hypericum perforatum) (49), Bacopa monnieri (50), and many
others. Perry and Howes (51) completed an informative review
on medicinal plants in dementia, pointing out the potential
cognitive benefits of a significant variety of plants and herbs. A
recent systematic review has found that tyrosine and caffeine
could enhance cognitive performance when healthy young adults
are sleep-deprived in a military context (52).Frontiers in Psychiatry | www.frontiersin.org 6Prescribed drugs:
Methylphenidate is undoubtedly the most prescribed CE, and
being indicated for the treatment of ADHD in many countries,
it is described, in this paper, within the “prescribed drugs”
group. The non-medical use of methylphenidate as a CE, which
involves an attempt to improve memory, increase mental
concentration, control anxiety, and stimulate motivation and
creativity, is rising worldwide (38, 53). Many other prescribed
drugs are being talked about in psychonauts’ blogs and fora
(Table 3).
Among the “prescribed drugs” family described by
NPSfinder® the SSRIs are also listed as a class. Research
studies have often failed to demonstrate that SSRIs can have
cognitive enhancing properties (54, 55). For example, neither
sertraline (54) nor citalopram (55) appeared to be superior to
placebo in improving cognition in patients with Alzheimer’s
disease and comorbid depression. It was also suggested that any
cognitive benefits of SSRIs were likely to be secondary to their
effect on mood or behavioral disturbances. However, a more
recent review on the topic concluded that the lack of evidence for
SSRIs as CEs or disease modifiers in Alzheimer’s disease is more
the result of omissions in clinical trial design, as opposed to
reports of negative evidence (56). Interestingly, both fluoxetine
and methylphenidate potentiate gene regulation in the striatum,
and their combination seems to mimic cocaine effects, with
related increased risk for substance use disorder (57).
It is possible that many prescribed drugs are currently being
misused by the general public but not picked up by the regulatory
bodies because the vast majority of them are not classified as illegal.
It is important that more studies and cross-sectional surveys are
conducted as well as that the current pharmacovigilance systems
focus on determining current patterns and quantifying current
usage of these drugs by healthy people.TABLE 2 | Plants/herbs/product (n=41; 29%).
1 Acetyl-L-carnitine
2 Areca nut
3 Arecoline (transdermal patch)
4 Bacopa monnieri
5 Caffeine
6 Catechins
7 Celastrus paniculatus
8 Cinnamon extract
9 Coumarins
10 Curcumin
11 Flavonoids
12 Ginger root extracts
13 Gingko biloba
14 Ginseng
15 Harmaline
16 Harmalol
17 Icariin
18 Kaempferol
19 Kava kava
20 Kratom
21 Lemon balm
22 Lobeline
23 Maca
24 Marijuana
25 Menthol
26 Mucuna pruriens
27 Naringin
28 Nicotine (patch)
29 Peganum harmala
30 Periwinkle
31 Quercetin
32 R-alpha-lipoic acid
33 Sakae naa
34 St John’s wort
35 Tannic acid
36 Vitamin A
37 Vitamin B12
38 Vitamin D
39 Withania somnifera
40 Yerba Mate
41 Yohimbine HCLTABLE 3 | Prescribed drugs (n=24; 17%).
1 123I-Ioflupane
2 Amphetamine/dextroamphetamine (Adderal)
3 Armodafinil
4 Atomoxetine
5 Dextroamphetamine
6 DL-Phenylalanine
7 Galantamine
8 Hydergine
9 Lisdexamfetamine
10 Melatonin
11 Memantine
12 Memantine extended release
13 Methylphenidate
14 Modafinil
15 Modafinil suphone
16 NSI-189
17 Quetiapine
18 S-adenosyl-methionine
19 Selegiline
20 Sildenafil
21 Stablon
22 Tadalafil
23 Tropicamide
24 VasopressinSeptember 2020 | Volume 11 | Article 546796
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Racetam compounds, which are classically one of the major CE
family (58), are identified by NPSfinder® and listed within the
IPEDs sub-group (Table 4).
Piracetam enhances cognitive function without causing
sedation or stimulation (3). This drug is also being used
in clinical practice for the treatment of several diseases
(59–62) although its mechanism of action remains not
fully understood.
NPSfinder® identified aniracetam, coluracetam, fasoracetam,
nefiracetam, oxiracetam, phenylpiracetam, piracetam, and
pramiracetam. Although all these substances have been
mentioned in the psychonauts’ fora as having nootropic
properties, research studies have not always succeeded in
demonstrating their cognitive enhancing qualities. For example,
recent studies failed in showing that aniracetam improves working
memory in pigeons (63), learning and memory in rats (64), or
cognitive and affective behavior inmice (65). Moreover, nefiracetam
did not prove to be more efficacious than placebo in ameliorating
apathy in stroke (66) despite some positive pre-clinical results (67,
68). One old study on pramiracetam has failed to demonstrate any
cognitive benefit from its administration to patients suffering from
Alzheimer’s disease (69). There are no available studies on
coluracetam, fasoracetam, and phenylpiracetam.
Psychostimulant drugs:
Among the psychostimulant CEs are described many derivatives
of methylphenidate and modafinil (Table 5). These have been
listed in this group when not licensed as prescribed drugs.
Methylphenidate is a prescription drug with medical
restrictions in several countries, therefore, many illegal
analogues have emerged on the internet and darknet drug
markets during the last few years (53). The derivatives of
methylphenidate that have been identified by NPSfinder®
include: 3,4-dichloromethylphenidate, 4-fluoromethylphenidate,Frontiers in Psychiatry | www.frontiersin.org 74-methylmethylphenidate, dexmethylphenidate, ethylphenidate,
methylmorphenate, and methylnaphthidate.
The derivatives of modafinil include: adrafinil, fladrafinil,
flmodafinil, and N-methyl-4,4′-difluoro-modafinil.
Miscellaneous:
The categories “miscellaneous” include amino-acids such as
tryptophan and L-tryptophan, 5-hydroxytryptophan, phenylalanine,
and theanine, as well as man-made chemicals such as vinpocetine
and sulbutiamine and other various molecules such as beta-asarone,
PRE-084, and RO-4491533. No research studies are available
regarding the misuse of these molecules by healthy subjects in
order to ameliorate their cognitive function (Table 6).
Phenethylamines:
The phenethylamines-related compounds that have been
identified by NPSfinder® are listed in Table 7.
These are stimulant, entactogenic, and hallucinogenic
substances that share similar chemical structures with
amphetamine, catecholamines, synthetic cathinones, and other
molecules (70).
Phenethylamines are known to enhance mood and empathy
in healthy subjects. Substituted phenethylamines also include
substituted amphetamines, which have been used as CEs toTABLE 4 | IPEDs (n=21; 15%).
1 Acetildenafil
2 Alpha GPC
3 Aminotadalafil
4 Aniracetam
5 Centrophenoxine
6 Choline Bitartrate
7 Citicoline
8 Creatine
9 Coluracetam
10 Dehydroepiandrosterone
11 Fasoracetam
12 Homosildenafil
13 Huperzine A
14 Lovegra
15 Nefiracetam
16 Noopept
17 Oxiracetam
18 Phenylpiracetam
19 Piracetam
20 Pramiracetam
21 VardenafilTABLE 5 | Psychostimulants drugs (n=21; 15%).
1 3,4-Dichloromethylphenidate
2 4 CTMP
3 4-fluoromethylphenidate
4 4-Mthylmethylphenidate
5 Adrafinil
6 Benzyl cyanide
7 Dexmethylphenidate
8 Dimethylaminoethanol
9 Ethylphenidate
10 Fladrafinil
11 Flmodafinil
12 L-655,708
13 Methylmorphenate
14 Methylnaphthidate
15 N-Methyl-4,4’-Difluoro-Modafinil
16 N-Methyl-cyclazodone
17 Pemoline
18 Prolintane
19 Razobazam
20 RO-4938581
21 TyrosineSeptember 202TABLE 6 | Miscellaneous (n= 11; 8%).
1 5-HTP
2 Beta-asarone
3 L-Tryptophan
4 Phenylalanine
5 PRL-8-53
6 PRE-084
7 RO-4491533
8 Sulbutiamine
9 Theanine
10 TRP
11 Vinpocetine0 | Volume 11 | Article 546796
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addiction (20). Dolder et al. (20) found that MDMA-induced
subjective, emotional, sexual, and endocrine effects that were
clearly distinct from those of methylphenidate and modafinil. To
the best of our knowledge, there are no research studies or case
reports focusing on the misuse of specific phenethylamines as
CEs by healthy subjects.
GABAergic drugs:
GABAergic drugs are chemicals that produce their effects via
interactions with the GABA system, such as by stimulating or
blocking neurotransmission (71).
Among these, GABA, tolibut, picamilon, phenibut, and f-
phenibut were discussed in the psychonauts’ fora as having
tranquillizing as well as nootropic properties (Table 8). There
is increasing evidence suggesting that phenibut, a potent
psychoactive substance with GABA-B agonist properties which
is often sold as a “dietary supplement”, can induce withdrawal
and physical dependence which makes its use dangerous (72–
76). f-phenibut, which is closely related to phenibut, is a central
nervous system depressant (72); tolibut is a GABA analog that
was developed in Russia (77), similarly to picamilon, which is
formed by a synthetic combination of niacin and g-aminobutyric
acid (GABA). Picamilon was developed in the Soviet Union in
1969 (78) and further studied in both Russia (79) and Japan (80)
as a prodrug of GABA.
Cannabimimetic:
Among Cannabimimetic drugs there are the synthetic
cannabimimetics that are designer drugs that target the
same receptors to which cannabinoids in cannabis plants,
tetrahydrocannabinol (THC) and cannabidiol (CBD) bind (81,
82). dexanabinol, drinabant, Dronabinol, JZL-184, rimonabant,
and URB-597 were the six CEs belonging to this group that were
identified by the NPSfinder® (Table 9).
The use of cannabimimetics as CEs seems counter-intuitive as
both pre-clinical and human studies have found a link betweenFrontiers in Psychiatry | www.frontiersin.org 8consumption of cannabinoids and long-term deficits of cognitive
functions, especially high-order cognitive functions (83–88).
However, recent pre-clinical studies have found that delta-9-THC
can improve cognitive performances in rats (89) and mice (90).
THC, in fact, appears to promote hippocampal neurogenesis to
prevent neurodegenerative processes occurring in animal models of
Alzheimer’s disease, to protect from inflammation-induced
cognitive damage, and to restore memory and cognitive function
in old mice (91).
Tryptamines derivatives:
5-Methoxytryptamine (5-MT, also called mexamine) (Table 10)
was the only tryptamine derivative identified by NPSfinder® (as
well as by the EWA). This is a tryptamine derivative closely
related to both the serotonin and melatonin neurotransmitters
(92). To the best of our knowledge, there are no studies, surveys,
or case reports that identified 5-MT as a drug used by healthy
people in order to improve their cognitive abilities. Jansen et al.
(93) reviewed the efficacy of melatonin in addressing cognitive
impairment in dementia but found the evidence for this to
be inconclusive.
Piperazine derivatives:
Fipexide (also known as attentil and vigilor) (Table 11) is the
only substitute piperazine that has been identified by NPSfinder®
as a CE. This was initially developed in Italy in 1983 (94) and
used as a CE in Italy and France for the treatment of dementia
(95). Fipexide is no longer in use due to the occurrence of rare
side-effects (96, 97). On psychonauts’ fora it is described as a
molecule able to improve short term memory, attention,
learning, and cognition.
Ethical, Clinical and Legal Issues
Ethical issues raised by cognitive enhancement have been debated
for over a decade (98), and many experts have identified multiple
ethical concerns including risks to mental and health safety (99).
While CEs hold significant benefits in improving cognitive
impairments in several neuropsychiatric disorders such as
Alzheimer’s disease (7–9) and schizophrenia (100), the use of
nootropics by healthy individuals clearly poses ethical, clinical,TABLE 7 | Phenethylamines (n=9; 6%).
1 2C-D
2 B-HO-Hordenine
3 Desoxypipradrol
4 Ephedrine
5 Geranamine
6 Hordenine
7 Isopropylphenidate
8 Octopamine
9 PropylphenidateTABLE 8 | GABAergic drugs (n=7; 5%).
1 F-Phenibut
2 GABA
3 Phenibut
4 Picamilon
5 PWZ-029
6 SH-053-R-CH3-2′F
7 TolibutTABLE 9 | Cannabimimetic (n=6; 4%).
1 Dexanabinol
2 Drinabant
3 Dronabinol
4 JZL-184
5 Rimonabant
6 URB-597September 2020 | Volume 11 | ATABLE 10 | Piperazine derivatives (n=1; 0.5%).
1 FipexiderticleTABLE 11 | Tryptamine derivatives (n=1; 0.5%).
1 Mexamin546796
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policy framework.
Mohamed and Sahakian (101) pointed out that CEs’ use in
healthy people might have some advantages, such as: helping
reduce disparity in society by mitigating the adverse
environmental effects (like poverty) on the brain; improving
the performances of people who need to perform at the best of
their abilities in every situation (such as surgeons or pilots);
finally CEs might also be used by people with undiagnosed
disorders (such as ADHD) who might be therefore self-
medicating with stimulant medications.
On the other hand, it is of concern that the safety and efficacy
of these drugs in healthy individuals in the long-term are still
unclear. While some CEs have been studied and research data on
their mechanism of action and potential benefit are available, the
action, the beneficial effects, and the potential side-effects of the
majority of them have yet to be fully described and understood.
Furthermore, CEs’ effects (if present at all) seem to be temporary,
lasting until their metabolism and elimination (102). Some of
these drugs can cause dependence and have a significant range of
harmful effects; they can be particularly dangerous to young
people as their brains are not fully developed. Studies producing
null results and some evidence of task-specific impairments
should be also noted (103).
The limited evidence of effectiveness as well as the potential
side-effects should be cautiously considered by relevant
legislative and regulatory bodies. In 2015, the US Presidential
Commission for the Study of Bioethical Issues (104) released a
report on CE, reporting up-to-date findings and providing
recommendations for clinicians (104). The Australian Alcohol
and Drug Foundation has recently raised doubts about the actual
cognitive benefits of most CEs, indicating that scientific studies
showed only little to no benefits for cognitive enhancement in
healthy individuals, while the associated side-effects do pose
significant risks to health and safety of the general public (105).
While further research is needed on the topic, the early
identification of CEs that are most commonly discussed on the
internet will increase clinicians’ awareness of this phenomenon
and potentially help them make clinical decisions for patients
presenting with psychiatric symptoms or physical health problems
related to these substances. NPSfinder® could also be an important
tool for analytical toxicologists to focus their efforts on the
detection of the most recently misused substances (106, 107).LIMITATIONS
In the online world, a significant variety of molecules/substances
are described as CEs by anecdotal report or unofficial sources; it
is important to note that the list of CEs is constantly evolving and
changing. An official, up-to-date, comprehensive list of CEs is
not currently available in the literature. The Early Warning
Systems fail in the early detection of these substances as they
are mostly legal products such as food supplements or prescribed
medication, which are misused by healthy individuals to improve
their cognitive abilities.Frontiers in Psychiatry | www.frontiersin.org 9In addition, there is a lack of an official classification of CEs in
families/categories. We based our classification on the one
described by Schifano et al. (44). We noted that another type
of classification, such as the one described by Froestl et al. (7–9)
which is based on substances’ pharmacodynamics properties, is
also relevant and useful and could be used when further data on
NPS pharmacological properties will be available.
In fact, many CEs do not have a fully understoodmechanism of
action, which makes it difficult to link them to a specific category;
other CEs have multiple mechanisms of actions (i.e. might target
several different receptors), and they could therefore belong to
more than one category; for example, one CEmight belong both to
the “prescription drugs” and the “GABAergic drugs” groups. Some
of the categories can themselves be very broad and have different
types of molecules belonging to it, for example “IPEDs”.
Furthermore, it is important to note that a limited number of
languages were used for the screening of molecules on the web,
and although many substances were first identified in seizures in
Asia, only European languages are used. For all these reasons,
forming a comprehensive and definite classification of CEs
remains a complex challenge.CONCLUSIONS
In this paper, three different databases, including the innovative
crawling software (NPSfinder®) and two official sources
(EMCDDA’s EDND, UNODC’s EWA) were cross-checked.
CEs are a wide and diverse group of molecules, constantly
growing in terms of numbers as well as availability among the
general public and especially via online platforms. CEs differ for
pharmacological activity, time, and mode of action, targeted
cognitive domain, pharmacodynamic and pharmacokinetic
properties, as well as possible short- and long-term side-effects.
The popularity of chemicals that are potentially able to augment
brain functions is not surprising in a society which constantly
demands for increasingly high cognitive performances.
For the current official Early Warning Systems, it is
challenging to identify and monitor the use of CEs as they are
often sold as legal food supplements or as prescribed medication
for a number of medical conditions. Due to its innovative
methodology, NPSfinder® has demonstrated its ability to
identify a higher number of CEs than the official EMCDDA’s
EDND and UNODC’s EWA (108). For this reason, NPSfinder®
can be considered as a helpful systematic tool which could
update clinicians with the growing numbers and types of
nootropics in the increasingly difficult-to-follow internet world.
Previously, Arillotta and colleagues (43) have identified 176
novel opioids which were not listed in either international or
European NPS databases, such as EMCDDA or UNODC. This
information is useful to stakeholders such as enforcement agents,
emergency department, scientific community, prevention
program setters, and other regulatory agencies. The same
applies to CEs; in particular, the early identification of
substances that are misused as CEs and the discovery of novel
CEs that were never reported or identified before are crucial toSeptember 2020 | Volume 11 | Article 546796
Napoletano et al. Psychonauts’ World of Cognitive Enhancersraise the awareness of regulatory bodies. The identification of a
drug is key to the treatment of its potential physical and
psychiatric effects; if the drug is novel, its description may shed
some light on its pharmacokinetics and toxicodynamics, which
would in turn inform treatment decision-making in
clinical settings.
Improving clinicians’ knowledge of CEs is of paramount
importance, and further research in order to clarify mechanism
of actions, as well as short- and long-term effects of many CEs is
also needed. The early identification and better understanding of
the distribution and effects of CEs could promote both more
effective prevention and harm reduction measures in clinical
settings, including emergency departments, mental health and
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ached to carbons R2 and R5 as well as a methyl
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otent stimulant drug related to methylphenidate. 3,4-
MP, the threo-diastereomer, is approximately seven
es more potent than methylphenidate in animal
dies, but has weaker reinforcing effects due to its
wer onset of action.
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vel stimulant substance of the tropane class.
mulant of the Phenyltropane class that acts as a
DRI. Yet being the Tropane analogue of 3,4-CTMP.
uoromethylphenidate belongs to the piperidine
emical class and is the 4-fluoro derivative of the
rnationally controlled substance methylphenidate
talin). It has been advertised online that 4-
romethylphenidate was developed as a replacement
ethylphenidate. Dosage indications and duration of
ct have also been suggested online.
ethylmethylphenidate is a ring methylated derivative
the piperidine compound methylphenidate, the active
armaceutical ingredient in the medicine Ritalin, which
sed in the treatment of ADHD. 4-
thylmethylphenidate has been researched as a
tential cocaine antagonist by blocking the binding of
caine to the dopamine transporter, when it was
orted to be a slightly more potent inhibitor of
pamine uptake, compared to methylphenidate (126
vs. 224 nM). [Deutsch 1996] - 4-
thylmethylphenidate is compound 1s in this paper,
thylphenidate is compound 1a.
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omnia. It is frequently used as a recovery supplement
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Y An RC analogue of sildenafil (Sildenafil) often missold as
a hidden ingredient in many ‘natural’ sexual potency
blends and supplements.
Y
Y Adderall is a psychostimulant drug, it is composed of 4
different amphetamine salts containing
Dextroamphetamine and Levoamphetamine. Its 4
different salts are: 1/4th Dextroamphetamine
Saccharate, 1/4th Dextroamphetamine Sulfate, 1/4
Racemic Amphetamine Aspartate Monohydrate, and 1/4
Racemic Amphetamine Sulfate.
N Adrafinil is very structurally similar to its close chemical
cousin and bioactive metabolite, modafinil. The only
structural difference is the that terminal amide hydroxyl
group of adrafinil ((diphenylmethyl)sulfinyl-2
acetohydroxamic acid) is lacking in modafinil
(diphenylmethyl)sulfinyl-2 acetamide). is a eugeroic that
was formerly used in France to promote alertness,
attention, wakefulness, mood, and other parameters,
particularly in the elderly.[3][4] It was also used off-label
by individuals who wished to avoid fatigue, such as
night workers or others who needed to stay awake and
alert for long periods of time. Additionally, “adrafinil is
known to a larger nonscientific audience, where it is
considered to be a nootropic agent.
Y Alpha-GPC is a naturally-occurring choline compound
found endogenously (naturally) in the brain which is also
made and used for oral consumption. Structurally,
Alpha-GPC is comprised of a choline group bound to a
glycerol molecule via a phosphate group.
N An analogue of tadafinil, better known as Tadalafil
(Sildenafil). Infamous for being missold in the ‘Alpha
Male’ sexual enhancement supplement.
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8 Acetildenafil Hongdenafil C25H34N6O3 N N
9 Acetyl-L-carnitine Tripsitter Party Supplement (3R)-3-acetyloxy-4-(trimethylazaniumyl)
butanoate
N N
10 Adderall Adderall XR, and Mydayis N/A N N
11 Adrafinil Olmifon; CRL40028 (+-)-2-Benzhydrylsulfinylethanehydroxamic
acid
Y Y
12 Alpha GPC choline alfoscerate; L-Alpha
glycerylphosphorylcholine;
[(2R)-2,3-Dihydroxypropyl] 2-
trimethylazaniumylethyl phosphate
N N
13 Aminotadalafil 385769-84-6
UNII-FY501QO030
FY501QO030
Amino-tadalafil
RR-ATDF
Tadalafil-Amino
Tadalafil, Amino
(2R,8R)-6-amino-2-(1,3-benzodioxol-5-yl)-
3,6,17-triazatetracyclo[8.7.0.03,8.011,16]
heptadeca-1(10),11,13,15-tetraene-4,7-
dione
N N2
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Aniracetam is a pyrrolidinone compound of the racetam
family, and has an additional anisoyl ring with a methoxy
group at the lone para position. (replacing the amine
group of piracetam) with an O-methoxy group on the
furthest binding point. Its structure is dissimilar to that of
oxiracetam (which is quite similar to piracetam) and
pramiracetam (a fairly unique structure) Aniracetam is
related structurally to nefiracetam.
The fruit of the Areca catechu palm tree, also known as
the “Betel Nut”, contain the stimulant arecoline. Native to
SE Asia, the nuts are ground and often combined with
mineral lime and wrapped in the leaf of a Betel pepper
plant, although they are sometimes consumed buccally
(‘chewed’) alone. Notably, frequent use can stain teeth
black and its daily use is associated with increased risk
of mouth cancers. Variants of the betel and lime
combination are extremely common in many Asian
cultures and have a long history of human use.
Arecoline is an alkaloid natural product found in oil form
in the areca nut, the fruit of the areca palm (Areca
catechu). In some Asian countries, areca nut is chewed
along with betel leaf to obtain a stimulating effect.
(R)-Modafinil, or Armodafinil, is a psychoactive molecule
of the benzhydryl class. Benzhydryl compounds are
comprised of two benzene rings attached to a single
carbon molecule. Armodafinil is classified as a sulphinyl
benzhydryl molecule, as it also contains a sulphinyl
group, a sulfur molecule double-bonded to an oxygen
molecule attached to the carbon of the benzhydryl
group.
Atomoxetine is a selective norepinephrine reuptake
inhibitor (SNRI) approved as a less stimulating treatment
for ADHD in 2002 (U.S.). The precise mechanism by
which it produces its therapeutic effects is unknown, but
is thought to be related to its SNRI action. It appears to
have minimal affinity for noradrenergic receptors or other
neurotransmitter transporters or receptors.
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14 Aniracetam methoxybenzoyl)-2-pyrrolidinon;
1-(p-methoxybenzoyl)-2-
pyrrolidinone; P-
METHOXYBENZOYL-2-
PIRROLIDONE;
AKOS005066313;
Tox21_110086_1; AB04115;
ACN-048215; API0001505;
BCP9000303; CCG-204210;
CS-1793; DB04599; KS-5313;
LP00115; NSC-758223; Ro-
135057; 2-Pyrrolidinone,1-(4-
methoxybenzoyl)-;
IDI1_000403;
1-[(4-Methoxybenzoyl)]-2-pyrrolidinone N N Y
15 Areca nut Betel nut; Paans (the
combination of Betel leaves,
lime, & Areca catechu)
N/A N N Y
16 Arecoline (transdermal patch) Methyl 1-methyl-1,2,5,6-
tetrahydropyridine-3-carboxylate
Y Y N
17 Armodafinil Nuvigil, Waklert, Artvigil, R-
Modawake, Neoresotyl; (R)-
Modafinil
2-[(R)-benzhydrylsulfinyl]acetamide N N Y
18 Atomoxetine Strattera (-)-N-methyl-3-phenyl-3-(o-tolyloxy)-
propylamine; (R)-N-methyl-3-phenyl-3-(o-
tolyloxy)propan-1-amine
Y N N
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Hordenine (N,N-dimethyltyramine) is an alkaloid of the
phenethylamine class that occurs naturally in a variety of
plants, taking its name from one of the most common,
barley (Hordeum species). Chemically, hordenine is the
N-methyl derivative of N-methyltyramine, and the N,N-
dimethyl derivative of the well-known biogenic amine
tyramine, from which it is biosynthetically derived and
with which it shares some pharmacological properties
It stimulates your grey matter and kicks it up a notch,
leaving you more time to enjoy the good things in life.
Benzyl cyanide is a useful precursor to numerous
pharmaceuticals. Examples include: Anorectics (e.g.
sibutramine)
It is one of the two isomers of Asarone, a chemical
compound of the phenylpropanoid class found in certain
plants such as Acorus and Asarum. It is no clear if can
be metabolized to trimethoxyamphetamine.
Caffeine is an alkaloid with a substituted xanthine core.
Xanthine is a substituted purine comprised of two fused
rings: a pyrimidine and an imidazole. Pryimidine is a six-
membered ring with nitrogen constituents at R1 and R3;
imidazole is a 5 membered ring with nitrogen
substituents at R1 and R3. Xanthine contains oxygen
groups double-bonded to R2 and R6.
Green tea (Camellia sinensis) plays an important role in
the traditional Chinese herbal medicine. Immediately
after harvesting the green tea leaves are steamed and
dried instead of fermented, so the bioactive ingredients
remains preserved optimally.
Celastrus paniculatus, also known as Black oil plant,
climbing staff tree and intellect tree is a woody, fruit-
bearing vine from India. Black oil plant seeds are used in
Ayurvedic medicine due to their varied medicinal
properties. Celastrus paniculatus’ ability to protect the
brain and to improve memory functions makes it an
effective nootropic.
Meclofenoxate is broken down by the liver into DMAE
and PCPA (parachlorphenoxyacetic acid). It has been
shown to cause mild memory improvement in people
with dementia and has been marketed as an anti-aging
supplement.
(Continued)
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19 B-HO-Hordenine 4-[2-(Dimethylamino)-1-hydroxyethyl]
phenol
N N Y
20 Bacopa monnieri Omnimind; Paneuromix N/A N N Y
21 Benzyl cyanide 2-Phenylacetonitrile; a-
Tolunitrile; Benzylnitrile
2-Phenylacetonitrile N N Y
22 Beta-asarone Cis-Isoasarone; (Z)-Asarone;
Cis-Asarone; cis-2,4,5-
Trimethoxyphenylprop-1-ene
1,2,4-Trimethoxy-5-[(1Z)-prop-1-en-1-yl]
benzene
N N Y
23 Caffeine Caffeine, Vivarin, Cafcit, Alert;
Caffeine; Vivarin; Cafcit;
Alert;1,3,7-trimethylxanthine,
methyltheobromine
1,3,7-trimethylpurine-2,6-dione N N Y
24 Catechins Green tea extract (2S,3R)-2-(3,4-dihydroxyphenyl)-3,4-
dihydro-2H-chromene-3,5,7-triol
N N Y
25 Celastrus paniculatus Black oil plant seeds N/A N N Y
26 Centrophenoxine Meclofenoxate; Amipolen;
Analux; Brenal; Cellative;
Centrophenoxin; Cerebron;
Cerutil; Closete; Helfergin;
lucidril; Lucidryl; Lutiaron;
Marucotol; Proserout; Proseryl;
Ropoxyl
2-Dimethylaminoethyl (4-chlorophenoxy)
acetate
N N Y
TABLE A1 | Continued
Unique to
PSfinder®
database
NPSfinder® Brief description
Choline is comprised of a quaternary ammonium group
and an alcohol functional group, which are connected
through an ethyl chain. Its charged cation can bind to a
negative group or atom to form various salts, which can
produce varying effects. Choline chloride can form a
low-melting deep eutectic solvent mixture with urea with
unusual properties.
Citicoline, or cytidine diphosphate-choline, is a naturally
occurring substance found in human cell tissue and
synthesized as a sodium salt as a supplement. Its
chemical structure is comprised of a cytidine nucleoside
attached to a choline group through a diphosphate
bridge. Citicoline is a chemical intermediary in the
biosynthesis of phosphatidylcholine, a major
phospholipid in cell membranes.
Coluracetam, or N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro
[2,3-b]quinolin-4-yl)-2-(2-oxo-1-pyrrolidinyl)acetamide, is
a synthetic compound of the racetam family. Racetams
share a pyrrolidine nucleus, a five-member nitrogenous
ring with a ketone bonded oxygen at R2.[2] This 2-
pyrrolidone ring is bound to the terminal carbon of an
acetamide group, an ethyl amide chain with a ketone
bond (C=O) at the alpha carbon.
(Continued)
N
apoletano
et
al.
P
sychonauts
’W
orld
ofC
ognitive
Enhancers
Frontiers
in
P
sychiatry
|
w
w
w
.frontiersin.org
S
eptem
ber
2020
|
Volum
e
11
|
A
rticle
546796
18N NPSfinder® name Other names IUPAC (isomerdesign) EDND
(April 2019)
UNODC
EWA NPS
(July 2019)
N
27 Choline Bitartrate CHOLINE BITARTRATE; 87-
67-2; CHOLINI BITARTRAS; 2-
Hydroxy-N,N,N-
trimethylethanaminium 3-
carboxy-2,3-
dihydroxypropanoate; 2-
(Hydroxyethyl)
trimethylammonium bitartrate;
Choline bitartrate, 97%; Choline
tartrate (1:1); and many others.
2-Hydroxy-N,N,N-trimethylethan-1-
aminium
N N Y
28 Cinnamon extract 2-methoxy-4-prop-2-enylphenol;[(E)-prop-
1-enyl]benzene
N N Y
29 Citicoline Neurocoline; cytidine
diphosphate-choline; CDP-
Choline; cytidine 5’-
diphosphocholine
(2R,3S,4R,5R)-5-(4-amino-2-
oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-
ylmethoxy-hydroxyphosphoryl 2-
(trimethylazaniumyl)ethyl phosphate
N N Y
30 Coluracetam acetoamide; AJ-08232; DS-
14004; HY-17553;
AX8209310; KB-271979;
ST2407347; TC-072260; 4CH-
017490; FT-0697594; Y1294;
463C819; J-690145; I14-
13061; High-affinity choline
uptake facilitator (CNS
disorders), Mitsubishi; High-
affinity choline uptake facilitator
(depression/anxiety), BrainCells;
Neurons growth promoting
compound (major depressive
disorder/anxiety), BrainCells; 1-
Pyrrolidineacetamide, 2-oxo-N-
(5,6,7,8-tetrahydro-2,3-
dimethylfuro(2,3-b)quinolin-4-
yl)-; N-(2,3-dimethyl-5,6,7,8-
tetrahydrofuro[2,3-b]quinolin-4-
yl)-2-(2-oxo-1-pyrrolidinyl)
acetamide and many others.
N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro
[2,3-b]quinolin-4-yl)-2-(2-oxo-1-
pyrrolidinyl)acetamide
N N Y
TABLE A1 | Continued
S
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Y Ingredient of wild lettuce. Biennial, growing up to 2-4
feet, maximum height of 6 feet (cultivated plants usually
smaller). The erect stem, springing from a brown tap-
root, is smooth and pale green, sometimes spotted with
purple. Leaves are from 6 to 18 inches long, flowers are
pale yellow, with large open clusters.
Y Creatine is a nitrogenous amino acid produced
endogenously and synthesized for consumption.
Synthetic creatine is usually made from sarcosine (or its
salts) and cyanamide which are combined in a reactor
with catalyst compounds. The reactor is heated and
pressurized, causing creatine crystals to form. The
crystalline creatine is then purified by centrifuge and
vacuum dried. The dried creatine compound is milled
into a fine powder for improved bioavailability. Milling
techniques differ, resulting in final products of varying
solubility and bioavailability. For instance, creatine
compounds milled to 200 mesh are referred to as
micronized
Y Turmeric and ginger do not only look like one another;
they also fit together very well! That’s proven with this
excellent, beneficial tea by TAKA Turmeric with Golden
Ginger. The delicious organic blend of turmeric and
ginger provides a warming and invigorating effect. The
black pepper and coconut increase the effect of the
active ingredient in turmeric: Curcumin. Do not wait any
longer for the perfect turmeric tea: order Golden Ginger.
Y DHEA supplements are said to increase energy,
enhance memory and cognitive function, improve
immunity, and reduce the effects of stress.
Dehydroepiandrosterone (DHEA), also known as
androstenolone, is an endogenous steroid hormone.
DHEA also has a variety of potential biological effects in
its own right, binding to an array of nuclear and cell
surface receptors, and acting as a neurosteroid and
neurotrophin. In addition to its role as a natural
hormone, DHEA is used as an over-the-counter
supplement and medication; for information on DHEA as
a supplement or medication
(Continued)
N
apoletano
et
al.
P
sychonauts
’W
orld
ofC
ognitive
Enhancers
Frontiers
in
P
sychiatry
|
w
w
w
.frontiersin.org
S
eptem
ber
2020
|
Volum
e
11
|
A
rticle
546796
19N NPSfinder® name Other names IUPAC (isomerdesign) EDND
(April 2019)
UNOD
EWA NP
(July 20
31 Coumarins Leonotis Leonurus flowers;
Monnier’s snow parsley seeds;
Leonotis Leeonorus 20X
extract; wild lettuce
chromen-2-one N N
32 Creatine N-Carbamimidoyl-N-
methylglycine,
Methylguanidoacetic acid;
Creatine; N-Carbamimidoyl-N-
methylglycine;
Methylguanidoacetic acid
2-[Carbamimidoyl(methyl)amino]acetic
acid
N N
33 Curcumin Turmeric tea golden ginger;
Turmeric drink golden cocoa
(1E,6E)-1,7-bis(4-hydroxy-3-
methoxyphenyl)hepta-1,6-diene-3,5-dione
N N
34 Dehydroepiandrosterone DHEA; androstenolone;
Prasterone
3S,8R,9S,10R,13S,14S)-3-hydroxy-
10,13-dimethyl-
1,2,3,4,7,8,9,11,12,14,15,16-
dodecahydrocyclopenta[a]phenanthren-
17-one
N NC
1
TABLE A1 | Continued
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Y N Desoxypipradrol, acts as a norepinephrine-dopamine
reuptake inhibitor (NDRI) developed by Ciba in the
1950s. Desoxypipradrol is closely related on a structural
level to the compounds methylphenidate and pipradrol,
all three of which share a similar pharmacological
action.2-DPMP is a powerful stimulant that has been
found in the product ‘Ivory Wave’. It was taken as a
‘legal high’ and has amphetamine-like stimulant effects
similar to speed. 2-DPMP effects can be both powerful
and long-lasting, with effects that can last as long as 5-7
days - some users have had to go to hospital for help.
N Y Cannabinoid
N Y Dexmethylphenidate, sold under the trade names
Focalin among others, is a central nervous system (CNS)
stimulant used in the treatment of attention deficit
hyperactivity disorder (ADHD) and narcolepsy.It is in the
phenethylamine and piperidine classes of medications. It
is the active dextrorotatory enantiomer of
methylphenidate.
(Continued)
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(April 2
35 Deoxypipradol 2-diphenylmethylpiperidine; 2-
DPMP; 2-
Diphenylmethylpiperidine 2-
benzhydrylpiperidine 519-74-4
Desoxypipradrol 2-
(Diphenylmethyl)piperidine
Piperidine, 2-(diphenylmethyl)-
Piperidine,2-(diphenylmethyl)-
2-DPMP AK-24338 2-
(Diphenylmethyl)piperidine; 2-
Benzhydrylpiperidine;
Desoxypipradol; Ivory Wave
2-diphenylmethylpiperidine Y
36 Dexanabinol ETS2101; Dexanabinol;
(6aS,10aS)-9-(Hydroxymethyl)-
6,6-dimethyl-3-(2-methyloctan-
2-yl)-6a,7,10,10a-tetrahydro-
6H-dibenzo[b,d]pyran-1-ol
(6aS,10aS)-9-(Hydroxymethyl)-6,6-
dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]
pyran-1-ol
N
37 Dexmethylphenidate D-threo-Methylphenidate;
Methyl D-phenidate; Focalin;
UNII-M32RH9MFGP; D-
Methylphenidate; 40431-64-9;
D-TMP; M32RH9MFGP;
CHEMBL827; CHEBI:51860;
Focalin; methyl (R)-phenyl[(R)-
piperidin-2-yl]acetate; D-MPH;
Attenade; dexmetilfenidato;
AC1L4BP3; SCHEMBL34326;
GTPL7554;
DUGOZIWVEXMGBE-
CHWSQXEVSA-N;
ZINC896711; 2-
Piperidineacetic acid, alpha-
phenyl-, methyl ester,
(alphaR,2R)
Methyl (2R)-phenyl[(2R)-2-piperidinyl]
acetate
ND
0
TABLE A1 | Continued
NPSfinder® Brief description
Dextroamphetamine is a potent central nervous system
(CNS) stimulant and amphetamine enantiomer that is
prescribed for the treatment of attention deficit
hyperactivity disorder (ADHD) and narcolepsy. It is also
used as an athletic performance and cognitive enhancer,
and recreationally as an aphrodisiac and euphoriant.
Dextroamphetamine was also used by military air, tank
and special forces as a ‘go-pill’ during fatigue-inducing
missions such as night-time bombing missions or
extended combat operations.
The amphetamine molecule exists as two enantiomers
(in other words, two different molecules that are mirror
images of one another), levoamphetamine and
dextroamphetamine. Dextroamphetamine is the more
active, dextrorotatory, or ‘right-handed’, enantiomer of
the amphetamine molecule. Pharmaceutical
dextroamphetamine sulfate is available as both a a
brand name and generic drug in a variety of dosage
forms.
DMAE is a precursor of choline and an anti-oxidant that
is found naturally in the brain. It is said to improve
memory and learning as well as increasing ability to
concentrate.
DL-Phenylalanine is a racemic mixture of phenylalanine,
an aromatic amino acid with antidepressant, analgesic
and appetite suppressant properties. The
antidepressant effect of DL-phenylalanine may be
accounted for by its precursor role in the synthesis of
the neurotransmitters norepinephrine and dopamine.
Elevated brain norepinephrine and dopamine levels are
thought to be associated with antidepressant effects.
This agent also plays a role in alleviating mood swings of
premenstrual syndrome (PMS), increasing energy and
mental alertness and heighten the ability to focus in
individuals with attention deficit hyperactivity disorder
(ADHD).
AVE-1625 is a highly potent, selective antagonist for the
CB1 receptor with Ki values of 0.16-0.44 nM. Drinabant
reached phase IIb clinical trials as obesity treatment in
the treatment of obesity but was shortly thereafter
discontinued, likely due to the observation of severe
psychiatric side effects including anxiety, depression,
and thoughts of suicide in patients treated with the now-
withdrawn rimonabant, another CB1 antagonist that was
also under development by Sanofi-Aventis.
(Continued)
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38 Dextroamphetamine Dexedrine; Metamina; Attentin;
Zenzedi; Procentra; Amfexa; D-
Amphetamine;
Dextroamphetamine sulphate;
Dexamfetamine;
Dexamphetamine
(2S)-1-Phenylpropan-2-amine N N Y
39 Dimethylaminoethanol DMAE; deanol; di-methyl-
amino-ethanol; DMEA
2-(Dimethylamino)ethanol N N Y
40 DL-Phenylalanine DLPA; 2-amino-3-
phenylpropanoic acid
2-amino-3-phenylpropanoic acid N N Y
41 Drinabant AVE-1625 N-{1-[Bis(4-chlorophenyl)methyl]azetidin-
3-yl}-N-(3,5-difluorophenyl)
methanesulfonamide
N N Y
TABLE A1 | Continued
®
NPSfinder® Brief description
Dronabinol – trade names Marinol and Syndros – is a
synthetic form of tetrahydrocannabinol (THC) approved
by the FDA as an appetite stimulant for people with
AIDS and antiemetic for people receiving chemotherapy.
Synthetically created D9-THC, the main psychoactive
ingredient in Cannabis.
Ephedrine is the active ingredient in Ephedra sinica. One
isomer (pseudoephedrine) is widely sold as a
decongestant while the other (ephedrine) is a commonly
used stimulant. Ephedrine is a medication and stimulant.
It is often used to prevent low blood pressure during
spinal anesthesia. It has also been used for asthma,
narcolepsy, and obesity but is not the preferred
treatment. It is of unclear benefit in nasal congestion. As
a phenethylamine, ephedrine has a similar chemical
structure to amphetamines and is a methamphetamine
analogue having the methamphetamine structure with a
hydroxyl group at the b position.
Ethylphenidate is a synthetic molecule of the substituted
phenethylamine class. It contains a phenethylamine core
featuring a phenyl ring bound to an amino -NH2 group
through an ethyl chain. It is structurally similar to
amphetamine, featuring a substitution at Ra which is
incorporated into a piperdine ring ending at the terminal
amine of the phenethylamine chain. Additionally, it
contains an ethyl acetate bound to R2 or its structure.
Ethylphenidate is structurally differed to methylphenidate
by elongation of the carbon chain. Ethyl- regards the
side chain of two carbon atoms, phen- indicates the
phenyl ring, id- is contracted from a piperidine ring, and
-ate indicates the acetate group containing the oxygens.
Ethylphenidate is a chiral compound, presumably
produced as a racemic mixture.
As with phenibut, F-Phenibut is a derivative of GABA,
except with a fluorine-substituted phenyl group in the b-
position of the molecule. It is a chiral molecule and thus
has two potential configurations as (R)- and (S)-
enantiomers.[4] It has an almost identical chemical
structure to baclofen (only replacing a chlorine with a
fluorine atom in the para-position of the phenyl
group).[5] Additionally, the widely prescribed
gabapentinoid pregabalin also possesses a similar
structure as phenibut, except that the phenyl group is
instead replaced with an isobutyl group.
(Continued)
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42 Dronabinol ultrapure THC; Namisol;
dronabinol; Marinol; syndros;
cesamet; d9-thc; d9–
tetrahydrocannabino; delta9-
tetrahydrocannabino; delta9-
thc
(−)-trans-D9-tetrahydrocannabinol N N Y
43 Ephedrine Ephedrine Erythro Isomer;
Ephedrine Hydrochloride;
Ephedrine Renaudin; Ephedrine
Sulfate; Erythro Isomer of
Ephedrine; Hydrochloride,
Ephedrine; Renaudin,
Ephedrine; Sal Phedrine; Sal-
Phedrine; SalPhedrine; Sulfate,
Ephedrine; Mini Thins; Sudafed;
Trucker’s Speed; (-)-alpha-(1-
methylaminoethyl)benzyl alcohol
(1R,2S)-2-(methylamino)-1-phenylpropan-
1-ol
N N Y
44 Ethylphenidate EPH Ethyl 2-phenyl-2-(piperidin-2-yl)acetate Y Y N
45 F-Phenibut Fluorophenibut; Fluorobut; b-
(4-flourophenyl)-GABA
5-amino-4-(4-fluorophenyl)-1-
hydroxypentan-2-one
N N Yo
r
e
TABLE A1 | Continued
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NPSfinder® Brief description
A substance in the racetam family. Appears to be a
GABA(B) agonist, and has shown to block memory
disruptions caused by Baclofen, another GABA(B)
Agonist. Similar to another compound in the racetam
family Coluracetam, it enhances High affinity choline
reuptake (HACU). It is a nootropic, and has been in
clinical trials for vascular dementia and attention deficit
hyperactivity disorder
Fipexide is a mild stimulant that is thought to indirectly
affect dopamine levels in the brain. It is said to improve
short term memory, attention, learning, and cognition.
There is a risk of serious liver damage and high fever
with use. Fipexide (Attentil, Vigilor) is a psychoactive
drug of the piperazine chemical class which was
developed in Italy in 1983. It was used as a nootropic
drug in Italy and France, mainly for the treatment of
senile dementia, but is no longer in common use due to
the occurrence of rare adverse drug reactions including
fever and hepatitis
Fladrafinil was described in a patent by Louis Lafon
Laboratories in the 1980’s, the same company that
developed the atypical psychostimulant adrafinil (CRL
40028) in the 1970’s. Fladrafinil is the 4,4’-difluoro
derivative of adrafinil. A substance closely related to
Adrafinil and Modafinil. It is the bis(p-fluoro) ring
derivative of Adrafinil.
Ingredients of wild Lettuce. Biennial, growing up to 2-4
feet, maximum height of 6 feet (cultivated plants usually
smaller). The erect stem, springing from a brown tap-
root, is smooth and pale green, sometimes spotted with
purple. Leaves are from 6 to 18 inches long, flowers are
pale yellow, with large open clusters.
Bisfluoro analogue Modafinil. Has been sold online as a
research chemical. Was patented in 2013. Is slightly
more potent than Armodafinil. CRL-40,940 (also known
as flmodafinil, bisfluoromodafinil and lauflumide) is a
selective dopaminergic reuptake inhibitor, and is the
bisfluoro analog of the eugeroic modafinil and has been
sold online as a designer drug.
Gaba is an inhibitory neurotransmitter found naturally in
the brain. Research suggests that increased levels of
gaba might help reduce the mental decline associated
with aging.GABA is sold as a dietary supplement.
(Continued)
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46 Fasoracetam NS-105; LAM-105; (5R)-5-oxo-
D-prolinepiperidinamide
monohydrate; NS-105; AEVI-
001; LAM 105; MDGN-001;
NFC 1
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-
one
N N Y
47 Fipexide Attentil; Vigilor; BP 662 1-(1,3-benzodioxol-5-ylmethyl)-4-[(4-
chlorophenoxy)acetyl]piperazine
N N Y
48 Fladrafinil CRL 40941; Fluorafinil;
fluoromodafinil
4;4-
difluorobenzhydrylsulfinylacetohydroxamic
acid
Y Y N
49 Flavonoids 2-phenylchromen-4-one N N Y
50 Flmodafinil lauflumide; bisfluoromodafinil;
RL-40-940
C15H13F2NO2S Y N N
51 GABA g-aminobutyric acid; gamma
aminobutyric acid
4-Aminobutanoic acid N N Y
TABLE A1 | Continued
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Y Galantamine is a complex alkaloid that is found
endogenously in certain plants and synthesized for
medical use. It is comprised of a fusion between a
methoxy substituted benzene ring to a hydrogenated
and methylated azepine ring along with a hydroxylated
benzofuran group.
N Also known as methylhexanamine, this
sympathetomimetic drug was developed as a nasal
decongestant by Eli Lilly in the 1940s. It has been used
as a weight loss aid and missold as a dietary
supplement and component of some energy drinks.
Carries a risk of heart attack, stroke and other life-
threatening cardiovascular issues. It may occur naturally
as a component of the oil extracted from the geranium
plant.
Y Ginger is an herbaceous tropical perennial grows 2-4
feet tall from an aromatic, tuberous root. Leaves are
grass-like and 6-12 inches long. Flowers are dense, red
and yellow cone-like spikes 3 inches long at the end of
a 6-12 inch stalk.
Y Ginkgo biloba contains ginkgolides that have a positive
effect on blood circulation and oxygen levels, which are
associated with brain performance and help maintain
cognitive function. Ginkgo contributes to a clear mind
and mental focus. The brain boosting effects of ginkgo
can help improve memory and memory recall, whether
you’re preparing for an exam or simply want to keep
your mind sharp. Effect Ginkgo has stimulating
properties. It has a positive effect on cognitive function
and mental alertness. Ginkgo helps maintain healthy
blood vessels.
Y Ginseng’s thin, single stem grows from a bud at the top
of the root that rises and separates into a whorl of
compound leaves. Small green flowers radiate,
umbrella-like from the end of a stalk and are eventually
replaced by red berries.
(Continued)
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52 Galantamine Razadyne; Reminyl; Nivalin;
Razadyne ER; Reminyl;
Lycoremine
(4aS,6R,8aS)-5,6,9,10,11,12-Hexahydro-
3-methoxy-11-methyl-4aH-[1]benzofuro
[3a,3,2-ef][2]benzazepin-6-ol
N N
53 Geranamine DMAA; methylhexanamine;
methylhexamine; geranamine;
geranium extract; geranium oil;
2-amino-4-methylhexane;
dimethylamylamine; DMAA;
1,3-dimethylamylamine; 1,3-
DMAA; 1,3-
dimethylpentylamine; 4-methyl-
2-hexanamine; 4-methyl-2-
hexylamine; orthan; Forthane;
Floradrene;
4-methylhexan-2-amine Y N
54 Ginger root extracts (E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-
en-3-one;1-(4-hydroxy-3-methoxyphenyl)-
5-methyldecan-3-one
N N
55 Gingko biloba Gingko biloba powder N/A N N
56 Ginseng Tartar Root; Five-fingers bis[3,4,5-trihydroxy-6-(hydroxymethyl)
oxan-2-yl] 2,3-dihydroxy-6b-
(hydroxymethyl)-4,6a,11,11,14b-
pentamethyl-
1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-
tetradecahydropicene-4,8a-dicarboxylate
N NC
1
TABLE A1 | Continued
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Harmaline is a fluorescent psychoactive indole alkaloid
from the group of harmala alkaloids and beta-carbolines.
It is the partially hydrogenated form of harmine. Various
plants contain harmaline including Peganum harmala
(Syrian rue) as well as the hallucinogenic beverage
ayahuasca, which is traditionally brewed using
Banisteriopsis caapi. Present at 3% by dry weight, the
harmala alkaloids may be extracted from the Syrian rue
seeds.
Harmalol is a bioactive beta-carboline and a member of
the harmala alkaloids.
An analogue of sildenafil (Sildenafil) with similar effects.
Has been missold in certain ‘herbal’ blends and dietary
supplements for sexual potency. Little is known about
the pharmacology or safety profile of this drug in
humans, potentially less potent than sildenafil.
Hordenine (N,N-dimethyltyramine) is an alkaloid of the
phenethylamine class that occurs naturally in a variety of
plants, taking its name from one of the most common,
barley (Hordeum species). Chemically, hordenine is the
N-methyl derivative of N-methyltyramine, and the N,N-
dimethyl derivative of the well-known biogenic amine
tyramine, from which it is biosynthetically derived and
with which it shares some pharmacological properties.
A compound that is extracted from the herbs of
Huperziceae family. Is known as an acetylcholinesterase
inhibitor, which stops an enzyme from breaking down
acetylcholine which results in increases in acetylcholine.
Is currently in preliminary trials for Alzheimer’s.
Ergoloid mesylates are ergot alkaloids which act as
neuroprotective anti-oxidants. They are also said to
increase blood flow to the brain and generally increase
cognitive abilities though the evidence is contradictory
on these points. It was approved by the FDA in 1951.
Horny goat weed extract 10% Icariin | 3 g - Epimedium
(Continued)
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57 Harmaline 7-methoxy-1-methyl-4,9-dihydro-3H-
pyrido[3,4-b]indole
N Y N
58 Harmalol 1-Methyl-4,9-dihydro-3H-pyrido[3,4-b]
indol-7-ol
N N Y
59 Homosildenafil methyl-sildenafil C23H32N6O4S N N Y
60 Hordenine 4-Hydroxy-N,N-
dimethylphenethylamin
4-(2-Dimethylaminoethyl)phenol N N Y
61 Huperzine A Amino-13-ethylidene-11-
methyl-6-aza-tricyclo
[7.3.1.0*2,7*]trideca-2(7),3,10-
trien-5-one(Huperzine A); (-)1-
Amino-13-ethylidene-11-
methyl-6-aza-tricyclo
[7.3.1.0*2,7*]trideca-2(7),3,10-
trien-5-one((-)-Huperzine A);
(1R,9R,13E)-1-Amino-13-ethylidene-11-
methyl-6-azatricyclo[7.3.1.02,7]trideca-2
(7),3,10-trien-5-one
N N Y
62 Hydergine Gerimal; Niloric; co-dergocrine
mesilate; dihydroergotoxine
mesylate; Ergoloid mesylates
(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-2-
hydroxy-5,8-dioxo-4,7-di(propan-2-yl)-3-
oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-
4-yl]-7-methyl-6,6a,8,9,10,10a-
hexahydro-4H-indolo[4,3-fg]quinoline-9-
carboxamide;methanesulfonic acid
N N Y
63 Icariin Horny goat weed extract 10%
Icariin
5-hydroxy-2-(4-methoxyphenyl)-8-(3-
methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-
trihydroxy-6-methyloxan-2-yl]oxychromen-
4-one
N N Yo
r
e
TABLE A1 | Continued
NPSfinder® Brief description
propylphenidate is a synthetic molecule of the
bstituted phenethylamine and piperidine classes. It
ntains a phenethylamine core featuring a phenyl ring
und to an amino (NH2) group via an ethyl chain. It is
ructurally similar to amphetamine, featuring a
bstitution at Ra which is then incorporated into a
peridine ring ending at the terminal amine of the
enethylamine chain. Additionally, it contains an
propyl acetate bound to R2 of its molecular structure,
noticeable departure from methylphenidate, which
ntains a methyl group in this position.
nnabinoid
ue Lotus flowers have also yielded a variety of
aloids, including kaempferol, which has mild MAOI
operties. Traditionally used as a narcotic, Nymphaea
erulea helps strengthen the male erection. Blue Lily
o contains powerful antioxidants. This versatile plant
s a lot to offer. Effect Blue Lotus has calming effects.
e main effect of the Blue Lotus 20X extract is
dative, calming and relaxing. Blue Lotus offers a very
ild, mind opening (hallucinogenic) experience. This
tent extract combines very well with red wine,
inging you into a euphoric and ecstatic state. Last but
t least, Blue Lotus has aphrodisiac qualities.
va is a tropical evergreen shrub with large heart-
aped leaves and woody stems. Its thick roots are
ashed or ground and made into a cold beverage used
ilarly to alcohol. It has a long history of ritual and
creational use in Pacific Polynesia and is now a
mmon herbal product.
atom is the common name for the plant Mitragyna
eciosa Korthals. It is a tree indigenous to Southeast
ia (Thailand, northern Malay Peninsula to Borneo); it is
ostly grown in the central and southern regions of
ailand, and only rarely in the northern part. There are
ore than 40 compounds in the leaves of M. multi-
lvent, including many indole alkaloids such as
itragynine (once thought to be the primary active
nstituent), mitraphylline, and 7-hydroxymitragynine
hich is currently the most likely candidate for the
imary active chemical in the plant). Other active
emicals in M. specials include raubasine,
ynchophylline, and corynantheidine, among many
hers.
(Continued)
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64 Isopropylphenidate IPH, IPPH; IPPD Propan-2-yl 2-phenyl-2-(piperidin-2-yl)
acetate
Y Y N Is
s
c
b
s
s
p
p
is
a
c
65 JZL-184 4-Nitrophenyl 4-[bis(2H-1,3-benzodioxol-
5-yl)(hydroxy)methyl]piperidine-1-
carboxylate
N N Y C
66 Kaempferol Blue Lotus 20X Extract; Blue
Lotus tincture 15X Extract;
Kratom X Blue Lilly Liquid;
Trichocereus Bridgesii Cutting;
Trichocereus Bridgesii
Monstruosus Cutting
3,5,7-trihydroxy-2-(4-hydroxyphenyl)
chromen-4-one
N N Y B
a
p
c
a
h
T
s
m
p
b
n
67 Kava Kava Kava; Piper methysticum;
Kawa; Awa; Waka; Lawena;
Sakau; Yaqona; Kaffa kaffa;
6-[(E)-2-(cyclohexa-1,5-dien-1-yl)ethenyl]-
4-methoxy-5,6-dihydro-2H-pyran-2-one
N N Y K
s
m
s
re
c
68 Kratom Mitragyna speciosa; krath`m
(Thai); ketum; kratum;
Methyl (E)-2-[(2S,3S,7aS,12bS)-3-ethyl-
7a-hydroxy-8-methoxy-2,3,4,6,7,12b-
hexahydro-1H-indolo[2,3-a]quinolizin-2-
yl]-3-methoxyprop-2-enoate
Y N N K
s
A
m
T
m
s
m
c
(w
p
c
rh
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u
o
o
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u
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It is a nootropic drug invented in 1996 by a team
working for Merck, Sharp and Dohme, that was the first
compound developed which acts as a subtype-selective
inverse agonist at the a5 subtype of the benzodiazepine
binding site on the GABAA receptor. It acts as an
inverse agonist at the a1, a2, a3 and a5 subtypes, but
with much higher affinity for a5, and unlike newer a5
inverse agonists such as a5IA, L-655,708 exerts its
subtype selectivity purely via higher binding affinity for
this receptor subtype, with its efficacy as an inverse
agonist being around the same at all the subtypes it
binds to.A radiolabelled form of L-655,708 was used to
map the distribution of the GABAA a5 subtype in the
brain, and it was found to be expressed predominantly
in the hippocampus, an area of the brain involved with
learning and memory. Activation of this subtype is
thought to be largely responsible for producing the
cognitive side effects displayed by many benzodiazepine
and nonbenzodiazepine drugs, such as amnesia and
difficulties with learning and memory, and so this led
researchers to conclude that a drug acting as an inverse
agonist at this subtype should have the opposite effect
and enhance learning and memory.
Tryptophan (symbol Trp or W) is an a-amino acid that is
used in the biosynthesis of proteins. Tryptophan
contains an a-amino group, an a-carboxylic acid group,
and a side chain indole, making it a non-polar aromatic
amino acid. It is essential in humans, meaning the body
cannot synthesize it: it must be obtained from the diet.
Tryptophan is also a precursor to the neurotransmitter
serotonin, the hormone melatonin and vitamin B3. It is
encoded by the codon UGG.
Lemon Balm is a perennial (its root survives the winter)
herb usually growing 1-2 feet (50 cm) tall. The leaves are
ovate to heart-shaped and mint-like. Its flowers are
white to yellowish in loose, small bunches and have a
lemony-minty smell and flavor. Lemon Balm is used in
foods and teas, as an insect repellant, and there is
evidence that it has anxiolytic, sedative, mood
improving, and nootropic effects. Some people report
distinct psychoactive effects taking it as a tea, snorting,
or smoking it, sometimes in combination with other
plants or drugs, though reports are inconsistent.
(Continued)
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69 L-655,708 9H-Imidazo[1,5-a]pyrrolo[2,1-c]
[1,4]benzodiazepine-1-
carboxylic acid, 11,12,13,13a-
tetrahydro-7-methoxy-9-oxo-,
ethyl ester, (13aS)-; Ethyl
(13aS)-7-methoxy-9-oxo-
11,12,13,13a-tetrahydro-9H-
imidazo[1,5-a]pyrrolo[2,1-c][1,4]
benzodiazepine-1-carboxylate;
130477-52-0; CHEMBL52030;
Ethyl 7-methoxy-9-oxo-11,12,13,13a-
tetrahydro-9H-imidazo[1,5-a]pyrrolo[2,1-c]
[1,4]benzodiazepine-1-carboxylate
N N Y
70 L-Tryptophan L-TRP (2S)-2-amino-3-(1H-indol-3-yl)propanoic
acid
N N Y
71 Lemon Balm N/A N N Y
TABLE A1 | Continued
®
NPSfinder® Brief description
This drug is a CNS stimulant often prescribed for ADHD,
narcolepsy and obesity. It is also a pro-drug for
dextroamphetamine, and functions as a method for
providing extended-release stimulation. It is sometimes
prescribed alongside an SSRI for depression.
Lisdexamfetamine (contracted from L-lysine-
dextroamphetamine) is a prodrug of the central nervous
system (CNS) stimulant dextroamphetamine, a
phenethylamine of the amphetamine class that is used in
the treatment of attention deficit hyperactivity disorder
(ADHD) and binge eating disorder. Its chemical structure
consists of dextroamphetamine coupled with the
essential amino acid L-lysine. Lisdexamfetamine itself is
inactive prior to its absorption and the subsequent rate-
limited enzymatic cleavage of the molecule’s L-lysine
portion, which produces the active metabolite
(dextroamphetamine).
Native Americans used lobelia to treat respiratory and
muscle disorders, and as a purgative. The species used
most commonly in modern herbalism is Lobelia inflata
(Indian tobacco). However, there are adverse effects that
limit the use of lobelia.
Lobelia has been used as “asthmador” in Appalachian
folk medicine.
Two species, L. siphilitica and L. cardinalis, were once
considered a cure for syphilis.
Herbalist Samuel Thomson popularized medicinal use of
lobelia in the United States in the early 19th century, as
well as other medicinal plants like goldenseal.
One species, Lobelia chinensis is used as one of the fifty
fundamental herbs in traditional Chinese medicine.
Several studies show that lobelia is ineffective in helping
people to quit smoking.
Lovegra 100 mg, the pink female equivalent to the blue
Viagra pill. Specificly developed for women, The Lovegra
pill improves blood flow in the genital area. For more
intense sexual satisfaction for women, will increase your
pleasure and the vaginal moisture is ensured during the
entire sex. Did you already discovered Lovegra? If not
… you have to try this!!!
Maca is an edible herbaceous biennial plant of the family
Brassicaceae that is native to South America in the high
Andes mountains of Peru. It is mostly used for sexual
and fertility problems.
(Continued)
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72 Lisdexamfetamine lisdextroamfetamine;
lisdexamphetamine; Tyvense;
Elvanse; Aduvanz; Venvanse;
Vyvanse
(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-
2-yl]hexanamide
N N Y
73 Lobeline derived from lobelia inflata 2-[(2R,6S)-6-[(2S)-2-hydroxy-2-
phenylethyl]-1-methylpiperidin-2-yl]-1-
phenylethanone
N N Y
74 Lovegra N/A N N Y
75 Maca Peruvian ginseng; Lepidium
meyenii; maca-maca; maino;
ayak chichira; ayak willku.
Macaridine.
N/A N N Yo
r
e
TABLE A1 | Continued
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Cannabis is an annual herbaceous flowering plant
indigenous to eastern Asia but now of cosmopolitan
distribution due to widespread cultivation. It has been
cultivated throughout recorded history, used as a source
of industrial fibre, seed oil, food, recreation, religious and
spiritual moods and medicine. Each part of the plant is
harvested differently, depending on the purpose of its
use. The species was first classified by Carl Linnaeus in
1753
Melatonin is comprised of a monoamine chain attached
to an indole ring at the third carbon. A monoamine chain
is made up of an amine group attached to an ethane
chain. This monoamine chain can be found in many
neurotransmitters, including histamine, dopamine,
adrenaline, and noradrenaline. It is also found in many
psychoactive substances such as members of the
tryptamine and phenethylamine chemical classes.
Memantine or 3,5-dimethyladamantan-1-amine is a
synthetic molecule classified as a substituted
adamantane derivative. Its core structure is adamantane,
a diamondoid of four interlocked cyclohexane rings in a
stable 3-dimensional lattice conformation. Memantine is
substituted with a methyl carbon at both R3 and R5; it
contains an amine substitution at R1. Its name is derived
from its structure, 3,5-dimethyladamantan-1-amine.
Memantine is an arycyclohexylamine, belonging to the
same category as ketamine and is a derivative of
amantadine (adamantan-1-amine). It was originally
synthesized in the late 1960s and like amantadine it is
an adamantan-amine based uncompetitive NMDAR
antagonists, used in the treatment of Alzheimer’s
disease and other dementias and is considered to be
‘well-tolerated’.
See above
The menthol classic. Knaster Fresh is a minty blend of
hemp aroma and Mentha Spicata. Arctic fresh.
Methylmorphenate is a benzylmorpholine and is a
derivative of the internationally controlled substance
methylphenidate (methyl alpha-phenyl-2-
piperidineacetate), where the piperidine ring has been
replaced by a morpholine ring. Methylphenidate is used
to treat attention-deficit hyperactivity disorder
(ADHD).Methylmorphenate possesses two chiral
carbons (stereocenters).
(Continued)
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76 Marijuana Indian hemp; marijuana;
Cannabis, Marijuana, Weed,
Pot, Mary Jane, Grass, Herb,
Devil’s Lettuce, Jazz Tobacco;
Cannabis; Marijuana; Weed;
Pot; Mary Jane; Grass; Herb;
Devil’s Lettuce; Jazz Tobacco
N/A N N Y
77 Melatonin N-Acetyl-5-methoxytryptamine N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]
acetamide
N N Y
78 Memantine Axura, Ebixa, Namenda,
Memary
3,5-Dimethyladamantan-1-amine Y Y N
79 Memantine extended release memantine ER; Namenda XR 3,5-Dimethyladamantan-1-amine Y Y N
80 Menthol Knaster Fresh 5-methyl-2-propan-2-ylcyclohexan-1-ol N N Y
81 Methylmorphenate N/A Y Y No
r
e
TABLE A1 | Continued
NPSfinder® Brief description
MP-28 (methylnaphthidate) is structurally related to
ethylphenidate (controlled under the 1971 UN
nvention) having a naphthalene ring instead of a
nzene ring.HDMP-28 has been found to have
inforcing effects in a study that examined the
inforcing efficacy of psychostimulants in primate brain
sue.
ethylphenidate, sold under various trade names, Ritalin
ing one of the most commonly known, is a central
rvous system (CNS) stimulant of the phenethylamine
] and piperidine classes that is used in the treatment of
tention deficit hyperactivity disorder (ADHD) and
rcolepsy. The original patent was owned by CIBA,
w Novartis Corporation. It was first licensed by the US
od and Drug Administration (FDA) in 1955 for treating
at was then known as hyperactivity.
ethylphenidate’s mechanism of action involves the
ibition of catecholamine reuptake, primarily as a
pamine reuptake inhibitor. Methylphenidate acts by
ocking the dopamine transporter and norepinephrine
nsporter, leading to increased concentrations of
pamine and norepinephrine within the synaptic cleft.
is effect in turn leads to increased neurotransmission
dopamine and norepinephrine.[10] Methylphenidate is
o a weak 5HT1A receptor agonist.
Methoxytryptamine, a tryptamine derivative that
turally occurs in the body at low levels. Apparently
hances dreams.
Methoxytryptamine (5-MT), also known as mexamine,
a tryptamine derivative closely related to the
urotransmitters serotonin and melatonin.
odafinil is a synthetic stimulant which is also known
der the trade names Modiodial in Europe and Provigil
the United Kingdom. It is approved for use in the
atment of daytime sleepiness associated with
rcolepsy. Research has also suggested that modafinil
ay be effective in the treatment of sleepiness disorders
her than narcolepsy i.e. idiopathic hypersomnia, night-
ift sleep disorder, obstructive sleep disorder,
structive sleep apnoea, multiple sclerosis, Parkinson’s
sease, myotonic dystrophy, depression, schizophrenia,
tention-deficit disorder and cocaine dependence and
thdrawal.
(Continued)
N
apoletano
et
al.
P
sychonauts
’W
orld
ofC
ognitive
Enhancers
Frontiers
in
P
sychiatry
|
w
w
w
.frontiersin.org
S
eptem
ber
2020
|
Volum
e
11
|
A
rticle
546796
30N NPSfinder® name Other names IUPAC (isomerdesign) EDND
(April 2019)
UNODC
EWA NPS
(July 2019)
Unique to
NPSfinder®
database
82 Methylnaphthidate CHEMBL1183494; hdmp-28;
DL-Threo-methylnaphthidate;
Methyl 2-(naphthalen-2-yl)-2-
(piperidin-2-yl)acetate; 2-
Piperidineacetic acid, alpha-2-
naphthalenyl-, methyl ester;
BDBM50327107;
ZINC29484313; and many
others.
Methyl (naphthalen-2-yl)(piperidin-2-yl)
acetate
Y Y N H
m
C
b
re
re
ti
83 Methylphenidate Methylphenidan; Phenidylate;
Concerta; Calocain; Daytrana;
Plimasine; Meridil; Ritalin;
Methyl phenidylacetate;
Methylfenidan; Metilfenidato;
Methylin; 113-45-1; Centedrin;
Methylofenidan; Centedein;
Tsentedrin; 4311/B Ciba;
Metadate; Methylphen;
Riphenidate; Centredin; Methyl
alpha-phenyl-alpha-(2-piperidyl)
acetate; alpha-Phenyl-2-
piperidineacetic acid methyl
ester; NCI-C56280; 2-
Piperidineacetic acid, alpha-
phenyl-, methyl ester; HSDB
3126; EINECS 204-028-6; C
4311; CHEMBL7
Methyl phenyl(piperidin-2-yl)acetate N N Y M
b
n
[3
a
n
n
F
w
M
in
d
b
tr
d
T
o
a
84 Mexamine meksamin; 5-
Methoxytryptamine; 5-MT; 2-(5-
Methoxy-1H-indol-3-yl)
ethanamine; meksamin; 5-
Methoxytryptamine; 5-MT; 2-(5-
Methoxy-1H-indol-3-yl)
ethanamine;
2-(5-Methoxy-1H-indol-3-yl)ethanamine N Y N 5
n
e
5
is
n
85 Modafinil 2-benzhydrylsulfinylethanamide;
Modiodial; Provigil; Alertec;
CRL-40476;
Diphenylmethylsulfinylacetamide
2-[(Diphenylmethyl)sulfinyl]acetamide Y N N M
u
in
tr
n
m
o
s
o
d
a
wD
o
e
s
e
e
t
a
o
o
h
h
o
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Modafinil sulphone is considered to be one of two
metabolites of modafinil, it being the minor metabolite.
Modafinil sulphone is structurally related to the
previously notified modafiendz which is the bis-fluoro-N-
methyl analogue of modafinil.The properties of modafinil
sulphone have not been described extensively in the
literature. It has been reported that this substance has
anticonvulsant activity and therefore may find use in the
“treatment of preclinical subconvulsive manifestations”,
further studies are required in this area. In other
research, it has been stated that modafinil sulphone is
pharmacologically active with a half-life of approximately
12 hours but it has been reported that it may also not
exert any significant activity in the brain or periphery.
Mucuna pruriens is a tropical vine growing from 3-18
meters with white to dark purple hanging flowers. It’s
bean-like pods are covered with long stinging hairs and
contain black, white, or tan seeds. The leaves, seeds,
stems and roots contain L-Dopa, Serotonin, 5-HTP, and
Nicotine, as well as N,N-DMT, Bufotenin, and 5-MeO-
DMT. It has a tradition of use as a Ayurvedic
aphrodesiac, treatment for parkinsons, ayahuasca
admixture, and coffee substitute.
2-{[bis(4-fluorophenyl)methyl]sulfinyl}-N-methylacetamide
is the bis-fluoro-N-methyl analogue of the substance
modafinil and is currently marketed by online sellers as a
nootropic substance called ‘modafiendz’. Modafinil is
used to treat excessive sleepiness caused by
narcolepsy, shift work sleep disorder and obstructive
sleep apnea/hypopnea and is marketed as a
prescription medication under a number of names in the
EU including; Modasomil, Modiodal, Modiwake, Provigil
and Vigil.
N-methyl-cyclazodone is an approximately 3x - 5x more
potent derivative of the nootropic and psychostimulant
compound Pemoline.
A tincture is one of the most convenient ways to get
your dose of Kanna. Kanna extract induces a general
feeling of euphoria and sociability, relaxation and
increased focus, coupled with an energetic feeling. All
natural: No chemicals or sugars have been added.
Ingredients: Sceletium tortuosum extract, distilled water,
naringin, glycerin, alcohol (14%). Content: 10ml (2
doses)
(Continued)
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86 Modafinil Sulphone CRL 41056 and USP Modafinil
Related Compound B
2-[(diphenylmethyl)sulfonyl]acetamide Y Y N
87 Mucuna pruriens Velvet beans; Cow Itch; Itching
Bean; Nescafe; Bengal velvet
bean; Florida velvet bean;
Mauritius velvet bean;
Yokohama velvet bean;
cowage; lacuna bean; Lyon
bean
N/A N N Y
88 N-methyl-4,4’-difluoro-
modafinil
N-Methylbisfluoromodafinil;
Dehydroxyfluorafinil;
Modafiendz N-meethyl-4,4-
difluoro-modafinil
2-{[bis(4-fluorophenyl)methyl]sulfinyl}-N-
methylacetamide
Y Y N
89 N-methyl-cyclazodone N-methyl-cyclazodone;2-
(cyclopropyl(methyl)amino)-5-
phenyloxazol-4(5H)-one
N-methyl-cyclazodone;2-(cyclopropyl
(methyl)amino)-5-phenyloxazol-4(5H)-one
Y Y N
90 Naringin Kanna 50X Tincture (2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-
6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-
3,4,5-trihydroxy-6-methyloxan-2-yl]
oxyoxan-2-yl]oxy-5-hydroxy-2-(4-
hydroxyphenyl)-2,3-dihydrochromen-4-
one
N N Yo
r
e
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N Y Nootropic compound of the racetam family. Seems to
enhance both GABAergic and cholinergic signalling.
Long term use appears to be neuroprotective. Fat
soluble.
N Y Nicotine (3-[(2S)-1-methylpyrrolidin-2-yl]pyridine) is a
naturally occurring bicyclic compound comprised of a
pyridine ring attached to the second carbon of a
pyrrolidine ring that has a methyl substituent on the
nitrogen. Pyridine is an unsaturated six-membered ring
structurally related to benzene but with a nitrogen
member. Nicotine additionally contains a substituted
pyrrolidine ring, which is a saturated five-membered ring
with one nitrogen member. These rings are bridged from
the R3 position of the pyridine ring to the R2 position of
the pyrrolidine ring.
Tobacco is an annual or bi-annual growing 1-3 meters
tall with large sticky leaves that contain nicotine. Native
to the Americas, tobacco has a long history of use as a
shamanic inebriant and stimulant. It is extremely popular
and well-known for its addictive potential.
N N Noopept, or N-phenylacetyl-L-prolylglycine ethyl ester, is
a synthetic peptide. A peptide is a chain of simple amino
acids linked by peptide bonds. Noopept contains a
phenylacetyl subunit bound to a small peptide chain of
proline and glycine. The proline amino acid is composed
of a carboxylic acid group bound to a pyrrolidine ring at
C2. The glycine amino acid is bound to proline with a
peptide bond and contains an amino group bound to
the free carbon of ethanoic acid. Noopept is structurally
similar to the endogenous neuropeptide
cycloprolylglycine, for which it is a prodrug. Noopept is a
dipeptide conjugate of piracetam although it is not a
racetam as it lacks a pyrrolidone cycle.
(Continued)
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(Apr
91 Nefiracetam DM-9384 N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-
1-yl)acetamide
N
92 Nicotine Nicotine; tabak; tabacco;
cigarettes; tobacco; Mapacho
(S)-3-[1-Methylpyrrolidin-2-yl]pyridine N
93 Noopept GVS-111; Noopept; Noopept;
GVS-111; Omberacetam
N-Phenylacetyl-L-prolylglycine ethyl este Yi
TABLE A1 | Continued
ND
l 2019)
UNODC
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Unique to
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NPSfinder® Brief description
Y N NSI-189 is considered an experimental drug that is
currently being investigated by Neuralstem Inc., for the
treatment of major depressive disorders (MDD). The
research into this drug has been funded by the Defense
Advanced Research Projects Agency (DARPA) and the
National Institutes of Health (NIH) in the United States.
Neuralstem states that NSI-189 “enables the creation of
neural stem cell lines from many areas of the CNS,
including the hippocampus” and “boost the generation
of new neurons”. This would be achieved by the
stimulation of neurogenesis of human hippocampus-
derived neural stem cells in-vitro and in-vivo. This drug
by Neuralstem is the first to undergo clinical trials and
the company plans to develop NS1-189 into an orally
administrable drug for the treatment of MDD, and other
cognitive disorders such as Alzheimer’s disease and
PTSD.
N Y Octopamine is an organic chemical closely related to
norepinephrine. In many types of invertebrates it
functions as an important neurotransmitter and
hormone, but in the human body it normally exists only
at trace levels and has no known function. Because it
shares some of the actions of norepinephrine,
octopamine has been sold under trade names such as
Epirenor, Norden, and Norfen for use as a
sympathomimetic drug, available by prescription. In
mammals, octopamine may mobilize the release of fat
from adipocytes (fat cells), which has led to its
promotion on the internet as a slimming aid. However,
the released fat is likely to be promptly taken up into
other cells, and there is no evidence that octopamine
facilitates weight loss. It is also used to treat
hypotension and as a cardiotonic.
(Continued)
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94 NSI-189 (4-Benzylpiperazin-1-yl)-[2-(3-
methylbutylamino)pyridin-3-yl]methanone
Y
95 Octopamine b-HO-HPEA 4-(2-amino-1-hydroxyethyl)phenol Ni
TABLE A1 | Continued
e to
der®
ase
NPSfinder® Brief description
Oxiracetam, or (RS)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)
acetamide, is a synthetic compound of the racetam
family. Racetams share a pyrrolidine nucleus, a five
member nitrogenous ring with a ketone bonded oxygen
at R2. This 2-pyrrolidone ring is bound to the terminal
carbon of an acetamide group, an ethyl amide chain
with a ketone bond (C=O) at the alpha carbon.
Oxiracetam is substituted with an additional hydroxy
group at R4, which is a chiral center for the molecule.
Oxiracetam is presumably produced as a racemate of its
enantiomers. Oxiracetam is structurally analogous to
piracetam, which lacks the R4 hydroxy substitution of
oxiracetam.
Syrian rue (Peganum harmala) is a desert plant that
grows from the Eastern Mediterranean, throughout the
Middle East and up to India, Mongolia and Manchuria.
The seeds have a long history of ritual and medicinal
use, mainly as an incense. The smoke is widely believed
to ward off the evil eye.
The brown, triangular seeds contain a high amount of
harmala alkaloids that have a MAO inhibiting effect. For
this reason Syrian rue became popular among western
psychonauts as an ayahuasca analogue.
A stimulant of the 4-oxazolidinone class. Was used as a
medication for ADHD and Narcolepsy, yet was pulled
from most markets due to liver failures among children.
Periwinkle is a very common creeping perennial with
dark green leaves and white, pink, to purple flowers. It
has a long history of use, although it is not commonly
used as an herbal remedy in modern treatments. The
plant contains alkaloids and tannins, with a major
alkaloid being vincamine, related to the semisynthetic
vinpocetine.
(Continued)
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96 Oxiracetam BCP06209; HY-B1715;
Tox21_110218;
Tox21_500933; AC-670; AN-
929; CGP 21690; CO0043; CT
848; MFCD00242951;
RW2749; s4270; AB05478;
ACN-001375; CCG-205014;
CS-8012; LP00933; MCULE-
8223030209; RP17379;
TRA0048419; KS-00000O50;
4- Hydroxy-2-oxopyrrolidine-N-
acetamide; 4-hydroxypyrrolidin-
2-on-1-yl acetamide and many
others.
(RS)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)
acetamide
N N Y
97 Peganum harmala Syrian Rue N/A N Y N
98 Pemoline SCHEMBL41636; Pemoline
(JAN/USAN/INN);
MLS000759491;
MLS001424026; Pemoline,
>=98% (HPLC);
DTXSID3023427;
NRNCYVBFPDDJNE-
UHFFFAOYSA-; HMS2051C08;
HMS3393C08; AOB87716;
NSC25159; 5-Phenyl-2-imino-
4-oxo-oxazolidin; and many
others.
(RS)-2-amino-5-phenyl-1,3-oxazol-4(5H)-
one
N N Y
99 Periwinkle Madagascar Periwinkle; Rosy
Periwinkle
N/A N N Y
TABLE A1 | Continued
NPSfinder® Brief description
Phenibut is a derivative of GABA with a phenyl group in
the b-position. It is a chiral molecule and thus has two
potential configurations, as (R)- and (S)-enantiomers. It
has almost the same structure of baclofen (lacking only
a chlorine atom in the para-position of the phenyl group)
and contains phenethylamine in its structure.Pregabalin
has the same structure as phenibut, except that the
phenyl group is instead an isobutyl group.
Phenylalanine is found naturally in the breast milk of
mammals. It is used in the manufacture of food and
drink products and sold as a nutritional supplement for
its reputed analgesic and antidepressant effects. It is a
direct precursor to the neuromodulator phenethylamine,
a commonly used dietary supplement. As an essential
amino acid, phenylalanine is not synthesized de novo in
humans and other animals, who must ingest
phenylalanine or phenylalanine-containing proteins.
Phenylpiracetam is based on the piracetam molecular
skeleton with an additional phenyl group attached to the
pyrrolidone nucleus, albeit at a different steric location
than the substituted phenyl groups observed on
aniracetam or nefiracetam. Due to the chiral center at
the fourth position of the pyrrolidinone ring, it can exist in
an S or R-isomer; the clinically used form is the racemic
mixture.[6]
An analogue of GABA that does pass the brain blood
barrier, which is then hydrolyzed into GABA and Niacin.
In which the GABA could produce an anxiolytic effect.
The Niacin as a vasodilator. And is usually used as part
of a nootropic stac
(Continued)
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100 Phenibut Fenibut, Phenybut, PhGABA;
b-Phenyl-g-aminobutyric acid
4-Amino-3-phenylbutanoic acid N Y N
101 Phenylalanine (S)-2-Amino-3-phenylpropanoic acid N N Y
102 Phenylpiracetam phenyl-; BRN 5030440; (2-
Oxo-4-phenylpyrrolidin-1-yl)
acetamide; 2-(2-Oxo-4-phenyl-
pyrrolidin-1-yl)-acetamide; AK-
81769; J-500892;
Carphedone; Fonturacetam
[INN]; phenypiracetam;
Carphedo; ACMC-1BLAK;
AC1Q4ZOM; AC1L30ZV;
Oprea1_208829;
Oprea1_429090;
MLS000113218; and many
others.
(R,S)-2-(2-oxo-4-phenylpyrrolidin-1-yl)
acetamide
N N Y
103 Picamilon GABA-NG; N-(3-
Carboxypropyl)nicotinamide;
UNII-0S5N9SEK4N;
0S5N9SEK4N; 4-[(pyridin-3-
ylcarbonyl)amino]butanoic acid;
Butanoic acid, 4-[(3-
pyridinylcarbonyl)amino]-; N-
nicotinoyl-gamma-aminobutyric
acid; 4-(pyridin-3-ylformamido)
butanoic acid; 4-(pyridine-3-
carbonylamino)butanoic acid;
4-[(Pyridine-3-carbonyl)amino]
butyric acid; Butanoic acid, 4-
((3-pyridinylcarbonyl)amino)-;
and many others.
4-(Pyridine-3-carbonylamino)butanoic acid N N Y
TABLE A1 | Continued
NPSfinder® Brief description
Piracetam, or 2-oxo-1-pyrrolidine-acetamide, is a
synthetic compound of the racetam family. Racetams
share a pyrrolidine nucleus, a five member nitrogenous
ring with a ketone bonded oxygen at R2.[3] This 2-
pyrrolidone ring is bound to the terminal carbon of an
acetamide group, an ethyl amide chain with a ketone
bond (C=O) at the alpha carbon.
Pramiracetam, or N-[2-(Diisopropylamino)ethyl]-2-(2-
oxopyrrolidin-1-yl)acetamide, is a synthetic compound of
the racetam family. Racetams share a pyrrolidine
nucleus, a five member nitrogenous ring with a ketone
bonded oxygen at R2. This 2-pyrrolidone ring is bound
to the terminal carbon of an acetamide group, an ethyl
amide chain with a ketone bond (C=O) at the alpha
carbon. Pramiracetam features an additional substituion
bonded to RN of the acetamide group of a ethyl amide
chain with two isopropyl carbon chains attached to the
terminal nitrogen. Pramiracetam is structurally analogous
to piracetam with an added diisopropyl ethylamino
chain.Pramiracetam is prepared from piracetam by
substituting the amide group with a dipropan-2-
ylaminoethyl group.
A sigma-1 receptor agonist derived structurally from
PCP. It has cognitive enhancing effects as well as
antidepressant effects, and shows promise in treating
many nervous system diseases such as ALS and
parkinsons.
A nootropic research chemical first synthesized in the
70s. One study shows a drastic improvement in mid-
term memory among users, but otherwise it is severely
lacking in information surrounding it. It has no
recreational potential.
(Continued)
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104 Piracetam MolPort-000-839-314;
NINDS_000259; HMS1569L15;
HMS1921L12; HMS2092D18;
HMS2096L15; HMS2230B24;
HMS3262N20; HMS3371G01;
HMS3657A05; HMS3713L15;
and many others.
2-(2-Oxopyrrolidin-1-yl)acetamide N N Y
105 Pramiracetam 68497-62-1; amacetam;
Pramiracetam [INN];
Pramiracetamum [INN-Latin];
UNII-4449F8I3LE; 1-
Pyrrolidineacetamide, N-(2-(bis
(1-methylethyl)amino)ethyl)-2-
oxo-; 4449F8I3LE;
C14H27N3O2; Neupramir;
Pramiracetam (INN); N-(2-
(diisopropylamino)ethyl)-2-(2-
oxopyrrolidin-1-yl)acetamide;
Pramiracetam hydrate; N-[2-[di
(propan-2-yl)amino]ethyl]-2-(2-
oxopyrrolidin-1-yl)acetamide;
and many others
N-[2-(Diisopropylamino)ethyl]-2-(2-
oxopyrrolidin-1-yl)acetamide
N N Y
106 PRE-084 PRE-084 Hydrochloride; Pre-
084; PRE-084 (hydrochloride);
138847-85-5; Pre 084; 75136-
54-8; 2-(4-Morpholinethyl) 1-
phenylcyclohexanecarboxylate
hydrochloride; SR-
01000076063; PRE-084, solid;
MLS000860067;
SCHEMBL7381926;
CHEMBL1449159;
CTK8E9795; MolPort-003-959-
092; BCP16863;
Tox21_500927; HY-18100A;
and many others
2-morpholin-4-ylethyl 1-
phenylcyclohexane-1-carboxylate
Y N N
107 PRL-8-53 Prl-8-53; 51352-88-6; methyl
3-[2-[benzyl(methyl)amino]ethyl]
benzoate; methyl 3-{2-[benzyl
(methyl)amino]ethyl}benzoate;
AC1L22UU; AC1Q5Z4V;
9043AF; ZINC31982738; AJ-
32456; 3-[2-[Benzyl(methyl)
amino]ethyl]benzoic acid methyl
ester
Methyl 3-[2-[benzyl(methyl)amino]ethyl]
benzoate
N N Y
TABLE A1 | Continued
Unique to
NPSfinder®
database
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Y 1-Phenyl-2-pyrrolidinylpentane (also known as Prolintane
or Pyrrolidinopentiophenone, and by the trade names
Catovit, Promotil, and Villescon) is a synthetic central
nervous system (CNS) stimulant that is structurally
similar to the substituted pyrrolidine class of compounds
such as MDPV and A-PVP albeit with notably attenuated
effects. Prolintane was first synthesized in the 1950s,
where it was found primarily to act as as a
norepinephrine-dopamine reuptake inhibitor (NDRI)[1]
which is thought to confer it stimulant and potential
nootropic qualities.
N Propylphenidate is structurally related to
isopropylphenidate from the piperidine and pyrrolidine
category of new psychoactive substances.
Propylphenidate and isopropylphenidate are also
structurally related to methyl- and ethylphenidate, where
the isopropyl or propyl is replaced with a methyl or ethyl
group. Propylphenidate can be synthesised from
methylphenidate.
Y PWZ-029 is a benzodiazepine derivative drug with
nootropic effects developed by WiSys,[1] It acts as a
subtype-selective, mixed agonist-inverse agonist at the
benzodiazepine binding site on the GABAA receptor,
acting as a partial inverse agonist at the a5 subtype and
a weak partial agonist at the a3 subtype. This gives it a
mixed pharmacological profile, producing at low doses
memory-enhancing effects but with no convulsant or
anxiogenic effects or muscle weakness, although at
higher doses it produces some sedative effects.
Y Description Endemic to the high Andean region of La
Paz, the Bolivian torch is a lesser known psychedelic
cactus containing several alkaloids including the
psychoactive alkaloid mescaline. Bioassay reports
indicate that Trichocereus bridgesii is much more potent
than the measured mescaline content suggests.
Capable of producing a mind-expanding kaleidoscopic
psychedelic experience, the effects of the Bolivian torch
have been described as more clear-headed than the
Peruvian torch. In Bolivia, the cactus is used as a hedge
plant, serving a practical and decorative function.
(Continued)
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108 Prolintane Prolintane; Prolintane;
Phenylpyrrolidinopentane;
Catovit; Katovit; Promotil;
Villescon
1-Phenyl-2-pyrrolidinylpentane N N
109 Propylphenidate PPH N/A Y Y
110 PWZ-029 CHEMBL45346; 6H-Imidazo
[1,5-a][1,4]benzodiazepin-6-
one, 8-chloro-4,5-dihydro-3-
(methoxymethyl)-5-methyl-;
SCHEMBL6847260;
BDBM50034820; 3-
Methoxymethyl-5-methyl-8-
chloro-4,5-dihydro-6H-imidazo
[1,5-a][1,4]benzodiazepin-6-one
8-Chloro-3-(methoxymethyl)-5-methyl-
4,5-dihydro-6H-imidazo[1,5-a][1,4]
benzodiazepin-6-one
N N
111 Quercetin Trichocereus Bridgesii Cutting;
Trichocereus Bridgesii
Monstruosus Cutting
2-(3,4-dihydroxyphenyl)-3,5,7-
trihydroxychromen-4-one
N N
TABLE A1 | Continued
NPSfinder® Brief description
Quetiapine is a dibenzothiazepine derivative. It is an
atypical antipsychotic agent and medicinal products
containing quetapine as the active pharmaceutical
ingredient (as quetiapine fumarate or quetiapine
hemifumarate) have been authorised in a number of
Member States for the treatment of schizophrenia and
for the prevention and treatment of bipolar disorder.
BrainBullets Core are capsules specially designed for
anyone who appreciates the importance of a healthy
brain. Core optimises your memory and protects your
brain. In this way you will give your upper deck the
essential vitamins it needs every day to keep your focus
and concentration at peak level. BrainBullets Core can
be ordered in packs of 15 or 30. Take one capsule each
day to maintain your cognitive performance in peak
condition.
It is a drug which is a benzodiazepine derivative. Its
mechanism of action appears to be quite different from
that of most benzodiazepine drugs, and it produces
nootropic effects in animal studies.
Rimonabant is the active pharmaceutical ingredient in
the medicinal product Acomplia, which was suspended
from the market in the European Union in November
2008 over concerns of serious psychiatric disorders
(including depression, sleep disturbances, anxiety, and
aggression) associated with its use. Acomplia was
withdrawn from the market in January 2009.
It is a drug developed by Hoffmann-La Roche which
acts as a potent and selective negative allosteric
modulator for group II of the metabotropic glutamate
receptors (mGluR2/3), being equipotent at mGluR2 and
mGluR3 but without activity at other mGluR subtypes. In
animal studies, RO-4491533 produced antidepressant
effects and reversed the effects of the mGluR2/3 agonist
LY-379,268 with similar efficacy but slightly lower
potency than the mGluR2/3 antagonist LY-341,495.
(Continued)
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112 Quetiapine Xeroquel; 2-{2-[4-(Dibenzo[b;f]
[1;4]thiazepin-11-yl)-1-
piperazinyl]ethoxy}ethanol; 11-
[4-[2-(2-hydroxyethoxy)ethyl]-1-
piperazinyl]dibenzo[b;f][1;4]
thiazepine; ICI 204;636
Ketipinor; quetiapine;
quetiapinum; ZM 204;636;
Seroquel
2-[2-(4-benzo[b][1,4]benzothiazepin-6-
ylpiperazin-1-yl)ethoxy]ethanol
Y N N
113 R-alpha-lipoic acid Core Memory Nootropics 5-[(3R)-dithiolan-3-yl]pentanoic acid N N Y
114 Razobazam UNII-LZ84VWN0U4; Hoe 175;
78466-98-5; LZ84VWN0U4;
4,8-Dihydro-3,8-dimethyl-4-
phenylpyrazolo(3,4-b)(1,4)
diazepine-5,7(1H,6H)-dione;
Pyrazolo(3,4-b)(1,4)diazepine-
5,7(1H,6H)-dione, 4,8-dihydro-
3,8-dimethyl-4-phenyl-; 5662;
and many others.
C14H14N4O2 3,8-Dimethyl-4-phenyl-2,8-
dihydropyrazolo[3,4-b][1,4]diazepine-5,7
(4H,6H)-dione
N N Y
115 Rimonabant SR-141716A; Acomplia;
SR141,716; Zimulti
5-(4-Chlorophenyl)-1-(2,4-dichloro-
phenyl)-4-methyl-N-(piperidin-1-yl)-1H-
pyrazole-3-carboxamide
Y Y N
116 RO-4491533 2H-1,5-Benzodiazepin-2-one,
4-[3-(2,6-dimethyl-4-pyridinyl)
phenyl]-1,3-dihydro-7-methyl-
8-(trifluoromethyl)-;
RO4491533;
CHEMBL1629855; D09YEQ;
GTPL6226;
SCHEMBL5562484;
BDBM50332963;
LYTVXCQQTLUEQR-
UHFFFAOYSA-N
4-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-7-
methyl-8-(trifluoromethyl)-1,3-dihydro-2H-
1,5-benzodiazepin-2-one
N N Y
TABLE A1 | Continued
NPSfinder® Brief description
4938581 is a nootropic drug invented in 2009 by a
am working for Hoffmann-La Roche, which acts as a
btype-selective inverse agonist at the a5 subtype of
e benzodiazepine binding site on the GABAA receptor.
has good selectivity for the a5 subtype and did not
oduce convulsant or anxiogenic effects in animal
udies, making it a promising potential nootropic.[1][2]
] Ro4938581 and a related derivative basmisanil (RG-
62, RO5186582) have subsequently been
estigated for the alleviation of cognitive dysfunction in
wn syndrome
adenosyl methionine is a molecule, found
dogenously as a substrate synthesized by the sub-
oups adenosine and methionine through an the
zyme methionine adenosyltransferase. The adenosine
bcomponent is comprised of an adedine nucleobase
nded to a ribose chain. This ribose chain is attached
the terminal carbon of the methionine group.
ethionine is a butyl carboxylic acid substituted at R2
th an amino group and at R4 with a methylthio
arbon-sulphur) group. S-adenosyl methionine is an
sential methyl donator in metabolic reactions.
kae Naa (Combretum quadrangulare) is a small tree
tive to Southeast Asia, the leaves of which are
portedly used as a substitute for kratom in areas
ere kratom is banned. There is dispute about
ether its effects are similar to the effects of kratom.
legiline increases the actions of dopamine in the brain
inhibiting the enzymes that break it down. After being
ld for years as an anti-aging supplement and a
atment for Parkinson’s disease, the FDA approved
e of a Selegiline transdermal patch (Emsam) for
atment of depression in 2006.
-053-R-CH3-2′F is a drug used in scientific research
ich is a benzodiazepine derivative. It produces some
the same effects as other benzodiazepines, but is
uch more subtype-selective than most other drugs of
is class, having high selectivity, binding affinity and
ficacy at the a5 subtype of the GABAA receptor. This
es much tighter control of the effects produced, and
while SH-053-R-CH3-2′F retains sedative and
xiolytic effects, it does not cause ataxia at moderate
ses.[1] SH-053-R-CH3-2′F also blocks the nootropic
ects of the a5-selective inverse agonist PWZ-029, so
nesia is also a likely side effect.
(Continued)
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117 RO4938581 9H-Imidazo[1,5-a][1,2,4]triazolo
[1,5-d][1,4]benzodiazepine, 3-
bromo-10-(difluoromethyl)-;
CHEMBL1080588; 883093-10-
5; RO 4938581; D0E7PY; 4-
tert.Butylcalix[8]arene;
GTPL4299;
SCHEMBL2426998; EX-A856;
AFJRYPJIKHMNGL-
UHFFFAOYSA-N;
BDBM50311045; and many
others.
3-Bromo-10-(difluoromethyl)-9H-imidazo
[1,5-a][1,2,4]triazolo[1,5-d][1,4]
benzodiazepine
N N Y R
te
s
th
It
p
s
[3
1
in
D
118 S-Adenosyl methionine SAM-e, Methylguanidoacetic
acid; S-Adenosyl methionine;
SAM-e; Methylguanidoacetic
acid
(2S)-2-Amino-4-(((2S,3S,4R,5R)-5-(6-
aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl)
methyl-methylsulfonio)butanoate
N N Y S
e
g
e
s
b
to
M
w
(c
e
119 Sakae naa Combretum quadrangulare 3-benzyl-1-hydroxy-2H-pyridine-4-
carbaldehyde
N N Y S
n
re
w
w
120 Selegiline Deprenyl; Eldepryl; Emsam; L-
deprenyl
(R)-N,a-dimethyl-N-2-
propynylbenzeneethanamine
N N Y S
b
s
tr
u
tr
121 SH-053-R-CH3-2′F 4H-Imidazo[1,5-a][1,4]
benzodiazepine-3-carboxylic
acid, 8-ethynyl-6-(2-
fluorophenyl)-4-methyl-, ethyl
ester, (4R)-; 872874-14-1;
SCHEMBL7718347;
NGYKELBMVXBFSM-
CQSZACIVSA-N;
ZINC35847341; KB-275294
Ethyl 8-ethynyl-6-(2-fluorophenyl)-4-
methyl-4H-imidazo[1,5-a][1,4]
benzodiazepine-3-carboxylate
N N Y S
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Sildenafil citrate is prescribed in the treatment of Erectile
Dysfunction. It is commonly referred to as a “lifestyle
drug”. Lifestyle drugs are prescribed for quality-of-life
conditions such as baldness, impotence, obesity and
smoking cessation. Sildenafil is a synthetic piperazine
derivative.
St. John’s wort, also known as “perforate” or “common”
St. John’s wort, is a plant with yellow flowers, that some
people, at first glance, may mistake for a common,
roadside weed. It has been used for centuries as an
herbal mood enhancer. Enjoy the rich flavour and effects
of one of Mother Nature’s miracle plants.
In terms of molecular structure and chemistry, tianeptine
is a tricyclic antidepressant as its molecular structure is
composed of three cyclic compounds. Despite
tianeptine’s chemical similarity to other TCAs, its effects
and mechanisms are fairly unique.
A thiamine derivative nootropic and stimulant drug.
Caution should be used as Sulbutiamine reduces
dopamine output over time with consistant usage.
Tadalafil, a PDE5 inhibitor used to combat erectile
disfunction. Dangerous in combination with other drugs
which lower blood pressure.
Use Guarana to get more energy. People who like a
boost can use this! It is now available in powder form.
Dissolve it in hot water, tea, hot milk, coffee or in any
another type of drink. Best is to first take one drink.
Then you can experience the effect on your body. If the
effect is pleasant, you can always try another drink.
Theanine, or N-ethyl-L-glutamine, is an amino acid
analogue of L-glutamine. Its structure is comprised of a
five carbon straight chain carboxylic acid called
pentanoic acid, which is bonded to an amino group at
R2, and an additional ketone group at R5. Also
substituted at R5 of the pentanoic group is an
ethylamino chain connected at its amino constituent.
Theanine is understood to refer to the levorotary
enantiomer, which is well documented, rather than the
relatively unresearched dextrorotary enantiomer.
(Continued)
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122 Sildenafil Viagra; Aphrodil 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-
propyl-1H-pyrazolo [4,3-d]pyrimidin- 5-yl)-
4-ethoxyphenyl]sulfonyl]-4-
methylpiperazine citrate
N N Y
123 St John’s wort St John’s Wort; Sint Janskruid N/A N N Y
124 Stablon Tianeptine, Stablon, Coaxil,
Tatinol; Tianeptine; Stablon;
Coaxil; Tatinol;Tianeptine
(RS)-7-(3-chloro-6-methyl-6,11-
dihydrodibenzo[c,f][1,2]thiazepin-11-
ylamino)heptanoic acid S,S-dioxide
Y N N
125 Sulbutiamine sulbut; arcalion; enerion;
bisibuthiamine; youvitan
4-[(4-amino-2-methyl-pyrimidin-5-yl)
methyl-formyl-amino]-3-[2-[(4-amino-2-
methyl-pyrimidin-5-yl)methyl-formyl-
amino]-5-(2-methylpropanoyloxy)pent-2-
en-3-yl]disulfanyl-pent-3-enyl] 2-
methylpropanoate
N N Y
126 Tadalafil Cialis; Adcirca; Tadacip (6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-
methyl-2,3,6,7,12,12a-hexahydropyrazino
[1’,2’:1,6] pyrido[3,4-b]indole-1,4-dione
N N Y
127 Tannic acid Guarana Powder [Paulinnia
Cupana]
[2,3-dihydroxy-5-[[(2R,3R,4S,5R,6S)-
3,4,5,6-tetrakis[[3,4-dihydroxy-5-(3,4,5-
trihydroxybenzoyl)oxybenzoyl]oxy]oxan-2-
yl]methoxycarbonyl]phenyl] 3,4,5-
trihydroxybenzoate
N N Y
128 Theanine Theanine, L-Theanine, L-g-
glutamylethylamide and N5-
ethyl-L-glutamine; Theanine; L-
Theanine; L-g-
glutamylethylamide and N5-
ethyl-L-glutamine
N-ethyl-L-glutamine; (2S)-2-ammonio-5-
(ethylamino)-5-oxopentanoate
N N Yi
t
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Y Analogue of GABA, and the 4-methyl analogue of
Phenibut. Has similar effects, acts on GABA(B).
N Medicinal products containing tropicamide are
authorised in the European Union. It is an antimuscarinic
used in medicinal products to dilate the pupils,
specifically as a topical mydriatic and cycloplegic.
Y Tryptophan (symbol Trp or W)[2] is an a-amino acid that
is used in the biosynthesis of proteins. Tryptophan
contains an a-amino group, an a-carboxylic acid group,
and a side chain indole, making it a non-polar aromatic
amino acid. It is essential in humans, meaning the body
cannot synthesize it: it must be obtained from the diet.
Tryptophan is also a precursor to the neurotransmitter
serotonin, the hormone melatonin and vitamin B3.[3] It is
encoded by the codon UGG.
Y Tyrosine is a non-essential phenylalanine-derived amino
acid. Tyrosine’s structure is made a para-hydroxylated
phenyl ring connected to a pentanoic acid group, which
is a five member carbon chain with a carboxyl (C(=O)
OH) group on the terminal carbon. This pentanoic acid
chain is substituted at R2 with an amino group in
levorotary orientation.
N URB-597 belongs to the carbamate chemical class. It is
known to be an inhibitor of the enzyme FAAH (fatty-acid
amide hydrolase) and this includes the metabolic
hydrolysis of the endocannabinoid/anandamide/(a fatty-
acid amide). It has been used extensively in
neuropharmacological research into endocannabinoid
system. It’s also known as KDS-4103. KDS-4103 is
being developed by Kadmus Pharmaceuticals, Inc. for
clinical trials in humans.
(Continued)
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129 Tolibut 28311-38-8; 4-amino-3-(4-
methylphenyl)butanoic acid; 4-
amino-3-(p-tolyl)butanoic acid;
AC1L2LNB; Oprea1_567181;
SCHEMBL18386267; 28311-
37-7 (hydrochloride); and many
others
4-Amino-3-(4-methylphenyl)butanoic acid N N
130 Tropicamide N-Ethyl-alpha-(hydroxymethyl)-
N-(4-pyridinylmethyl)
benzeneacetamide;
Visumidriatic; Mydriaticum;
Mydriafair; Tropicacyl;
Mydriacyl; Paremyd; Minims
tropicamide; Mydrum;
Bistropamide
(RS)-N-ethyl-3-hydroxy-2-phenyl-N-
(pyridin-4-ylmethyl)propenamide
Y N
131 Tryptophan 2-Amino-3-(1H-indol-3-yl)
propanoic acid; Trp; W; TRP
(2S)-2-amino-3-(1H-indol-3-yl)propanoic
acid
N N
132 Tyrosine L-Tyrosine or 4-
hydroxyphenylalanine; Tyrosine;
L-Tyrosine or 4-
hydroxyphenylalanine
L-Tyrosine N N
133 URB-597 KDS-4103; Cyclohexylcarbamic
acid 3’-carbamoyl-biphenyl-3-yl
ester
[3-(3-Carbamoylphenyl)phenyl] N-
cyclohexylcarbamate
Y N
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Besides Cialis (Tadalafil) we now offer Valif 20
(Vardenafil). Valif 20 improves erection and results in
successful intercourse. Valif 20 is also known as
Vardenafil. The effects of Valif 20 are noticeable 15 to 25
minutes after ingestion. In the absence of sexual arousal
Valif 20 will not work optimally. So make sure you are in
a horny environment
Vasopressin is a hormone produced in the
hypothalamus which increases water retention.
asopressin is used to manage anti-diuretic hormone
deficiency. It has off-label uses and is used in the
treatment of gastrointestinal bleeding, ventricular
tachycardia and ventricular defibrillation.
Vinpocetine is a derivative of vincamine from the
periwinkle plant. It increases cerebral blood flow and is
said to improve memory.
Vitamins are organic (carbon-containing) molecules that
are necessary for the functioning of the human body.
They have a wide range of effects and functions.
See above
See above
Is an Adaptogen. It is commonly used for its ability to
prevent anxiety. It also is helpful in relieving insomnia. It’s
name means “Smell of Horse” due to its smell and the
traditional belief that ingesting the this herb will give you
the strength and virility of a horse.
Ilex paraguariensis is a small S. American tree that’s
leaves contain caffeine and other xanthines. The toasted
leaves have a long history of use as a stimulant tea.
Falsely rumored to contain a unique chemical mateine.
Pausinystalia yohimbe is a West African tree thats bark
contains yohimbine. It has a long history of human use
as a stimulant and aphrodisiac. It is commonly sold as
an herbal supplement to improve erectile function.
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134 Vardenafil Valif 20 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)
sulfonylphenyl]-5-methyl-7-propyl-3H-
imidazo[5,1-f][1,2,4]triazin-4-one
N N Y
135 Vasopressin ADH; Pressyn; Diapid (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
butanamide
N N Y
136 Vinpocetine Cavinton; ethyl apovincaminate ethyl (15S,19S)-15-ethyl-1,11-
diazapentacyclo[9.6.2.02,7.08,18.015,19]
nonadeca-2,4,6,8(18),16-pentaene-17-
carboxylate
N N Y
137 Vitamin A (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-
tetraen-1-ol
N N Y
138 Vitamin B12 alpha-(5,6-Dimethylbenzimidazolyl)
cobamidcyanide
N N Y
139 Vitamin D (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-
methyl-1-[(2R)-6-methylheptan-2-yl]-
2,3,3a,5,6,7-hexahydro-1H-inden-4-
ylidene]ethylidene]-4-
methylidenecyclohexan-1-ol
N N Y
140 Withania somnifera Ashwagandha, an Indian
ginseng
(2R,6S,7R,9R,11S,15R,16S)-6-hydroxy-
15-[(1S)-1-[(2R)-5-(hydroxymethyl)-4-
methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-
2,16-dimethyl-8-oxapentacyclo
[9.7.0.02,7.07,9.012,16]octadec-4-en-3-
one
N N Y
141 Yerba mate South American holly;
Beverage: yerba mate;
Paraguay tea; Braziliain tea;
jesuit tea; ka’a (Guarani)
N/A N N Y
142 Yohimbine HCL Yohimbe methyl (1S,15R,18S,19R,20S)-18-
hydroxy-
1,3,11,12,14,15,16,17,18,19,20,21-
dodecahydroyohimban-19-carboxylate;
hydrochloride
N N Y
The 35 CEs described as nootropic in NPSfinder® are in bold.S
